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Abstract 
Introduction: Intraventricular haemorrhage (IVH) is a subtype of intracerebral haemorrhage (ICH), with 50% 
mortality and serious disability for survivors. CLEAR III, a randomised, double-blinded, placebo-controlled trial 
of subjects with a routinely-placed extraventricular drain (EVD), tested whether attempting to remove IVH with 
alteplase vs. saline irrigation improved functional outcome.  
Methods: Patients in the intensive care unit with stable, non-traumatic ICH volume <30 mL, IVH obstructing 
the 3rd or 4th ventricles, and no underlying pathology were adaptively randomised (1:1) to receive up to 12 
doses, 8 hours apart of 1mg of alteplase or 0.9% saline via the EVD. CT scans were obtained every 24 hours 
throughout dosing. The primary efficacy outcome was good functional outcome, defined as a modified Rankin 
Scale score of ≤3 at 180 days (mRS) per central adjudication by blinded evaluators. 
Results: The trial completed with 180-day follow-up data available for analysis from 246/251 and 245/249 
subjects in the alteplase and placebo groups, respectively. The primary efficacy outcome was similar in each 
arm (good outcome in alteplase group 48% vs. saline 45%; RR (95% CI)=1.06 (0.88, 128) p=0.554). A 
difference of 3.5% (RR (95% CI)=1.08 (0.90, 1.29), p=0.420) was found after adjusting for IVH size and 
thalamic ICH. At 180 days, the treatment arm had lower case fatality (18% vs. saline 29%, HR (95% CI)=0.60 
(0.41, 0.86), p=0.006), but greater proportion with mRS 5 (17% vs. 9%; RR (95% CI)=1.99 (1.22, 3.26), p 
=0.005). Ventriculitis (7% alteplase vs. 12%; RR (95% CI)=0.55 (0.31, 0.97), p=0.048), and serious adverse 
events (49% alteplase vs. 63%; RR (95% CI)=0.77 (0.66, 0.91), p=0.002), were less frequent with alteplase 
treatment. Symptomatic bleeding (2%, both arms; RR (95% CI)=1.21 (0.37, 3.91), p=0.771) was similar.  
Conclusions:  In patients with IVH and a routine EVD, irrigation with alteplase did not substantially improve 
functional outcomes at the mRS 3 cutoff compared to irrigation with saline. Protocol-based use of alteplase 
with EVD appears safe. Future investigation is needed to determine if a greater frequency of complete IVH 
removal via alteplase produces gains in functional status.    
 
 
(Funded by the National Institute of Neurological Disorders and Stroke; ClinicalTrials.gov NCT00784134.) 
Word count with research in context is 4669 
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Introduction: In patients with spontaneous intracerebral haemorrhage (ICH), intraventricular haemorrhage 
(IVH) is associated with devastating consequences.1-4 Mortality is reported to be greater than 50%, with fewer 
than 20% of survivors having good functional outcomes. Mortality and function appear to be altered if 
thrombolytic is employed.5,6 Systematic review, Meta-analysis suggest removal of IVH improves survival and 
long-term functional outcome by relieving acute obstructive hydrocephalus and reducing neurotoxicity.5-9 We 
hypothesised that small ICH with large IVH describes a subgroup of ICH patients whose severe prognosis is 
reversible.1,6 Thus we organised the Phase III Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR III) 
trial.  
 
In EVD-treated IVH subjects, we tested the hypothesis that irrigating the ventricle with alteplase would be 
superior to normal saline (0.9%), measured by an improved modified Rankin Scale (mRS) score 0-3 (mRS ≤3, 
called “good outcome”), in which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, 
and a score of 6 indicates death. This hypothesis was based on our preliminary data showing alteplase 
(Genentech, Inc., San Francisco, CA) can safely remove clot from the ventricle, if precautions are taken to 
avoid re-activating brain bleeding, in patients treated with an EVD.10-13 Although EVD placement is not 
standardised in practice for all cases of IVH, it is used to manage hydrocephalus and intracranial pressure 
(ICP). We included such patients in the CLEAR III study.  
 
Methods  
 
Trial Design and Participants: CLEAR III was a multicentre, randomised (1:1), prospective phase III trial11 
done at 73 sites in the US, Canada, Brazil, Israel, UK, Germany, Hungary, and Spain, following local and 
country ethics approval, testing a strategy of ventricular clearance with alteplase via EVDs placed for ICP 
control in subjects with a clinical diagnosis of obstructive hydrocephalus. Placement of an EVD pre-trial was a 
routine clinical care decision. Subjects were age 18-80 with known symptom onset within 24 hours of the initial 
computed tomography (CT) scan confirming IVH and 3rd or 4th ventricle obstruction. Eligibility criteria included 
supratentorial ICH volume ≤30 mL, measured by the ABC/2 method,12 and clot stability (no measured 
expansion >5 mL) on repeat CT scan at least 6 hours after EVD placement.13 Additional eligibility criteria 
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included an historical mRS ≤1, no limitations to care, and no ongoing coagulopathy, suspicion of aneurysm, 
arteriovenous malformation, or other vascular anomaly.13 (See supplemental appendix, section 2a. 
Methodological details of the treatment protocol: Inclusion and Exclusion criteria for additional details.) All data 
were captured electronically and pertinent source documentation uploaded by local site personnel using an 
internet-based electronic data capture (EDC) system (VISION, Prelude Dynamics, LLC, Austin, Tx). The EDC 
provided field-level and form-to-form range and value edit checks during data entry. Independent quality 
assurance monitors (Emissary International, LLC, Austin, Tx) utilized the uploaded source documentation to 
perform risk-based, remote monitoring of key data variables. Monitored data were then exported by the data 
management center where additional data edit checks were applied prior to form/subject finalization. Site 
personnel were notified of and responded to data discrepancies identified during these review processes using 
the EDC system query tool, with resulting data corrections captured by the electronic audit trail. 
 
Randomization and Blinding: All subjects and trial personnel except for the local and central pharmacists 
and the unblinded statistician were masked to treatment assignments. After the local PI determined eligibility 
and written, informed consent was obtained, site personnel randomised patients within 72 hours of ictus using 
a web-based enrollment system (VISION, Prelude Dynamics, LLC, Austin, Tx), which generated a treatment 
allocation and emailed the treatment assignment code directly to the local, trained pharmacist. All other site 
and coordinating center personnel remained blinded to allocation.  After 100 subjects were assigned by simple 
randomisation, a Pocock-Simon14,15.covariate adaptive algorithm was implemented to balance study arms by 
baseline IVH size (≤20 mL; 20-50 mL; and >50 mL, measured on the diagnostic CT), ICH location (thalamus or 
other, determined by centralised CT reading). Imbalances in these factors were determined at each enrollment, 
and patients were randomised with a weighted coin (80/20) favoring assignment to the treatment arm, which 
improved balance in ICH location and ICH size. 6,13,14 To ensure treatment balance at the site, patients were 
adaptively randomised only after a given site had recruited two saline and two alteplase patients. All 
participants remained masked during data collection and interim analyses. Masking was evaluated by 
the external monitor.  
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Treatment: Subjects received up to 12 doses, 8 hours apart, of 1 mg of alteplase or 0.9% saline via the EVD. 
CT scans were obtained every 24 hours throughout dosing. All subjects were managed using the American 
Heart Association recommendations for the treatment of spontaneous ICH as the basis for a standard 
approach to airway, ventilation, ICP monitoring, sedation and pharmacologic treatment of mass effect.16,17 
Investigators were asked to remove as much clot as possible, until a stopping point was obtained: 3rd and 4th 
ventricles open; IVH mass effect relieved; 80% of clot was removed; or 12 doses were given.   
 
Image analysis: To optimize accuracy and minimize investigator bias, clot volumes were analyzed by a core 
laboratory utilizing semi-automated segmentation and Hounsfield thresholds.18 This was performed using 
OsiriX software (v.4.1, Pixmeo; Geneva, Switzerland) on DICOM images of each subject’s stability and 
treatment scans. This approach has been validated for accuracy and inter-rater reliability.19 Core lab values 
were utilized in all analyses. Core lab defined location as either thalamus or other (lobar, putamen, caudate). 
 
Follow-up and Outcomes: Subjects were followed with an NIHSS assessment at Day 7, clinic visits on Days 
30, 180, and 365, and phone contacts at Days 90 and 270. A site-identified, certified examiner assessed the 
mRS, extended Glasgow Outcome Scale (eGOS; 8 level disability scale from 8-upper good recovery to 1-
death), Barthel Index (BI; 0 to 100 daily activities scale with 0 indicating no activities performed and 100 all 
activities performed), Stroke Impact Scale (SIS; self-reported scale of 16 activity domains from 1-most 
impaired to 5-not impaired), NIH Stroke Scale (NIHSS, clinic visits only; scores range from 0 to 42, with higher 
scores indicating a more severe neurologic deficit). CT was repeated at 30 and 365 days. The mRS 
assessment, the primary outcome, was video-recorded and sent to a core lab for blinded assessment by an 
independent panel of experts.13 All other assessments were secondary. Full details of mRS, eGOS, and 
NIHSS are given in the supplemental appendix sections 2b and 2c.   
 
Statistical Methods  
 
Sample Size: The trial planning was informed by data from the previously completed Phase II CLEAR studies, 
which recorded 30-day outcomes.6 Sample size planning assumed an average removal difference attributable 
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to alteplase of 12ml. The sample size of CLEAR III was planned to be 250 patients per group in order to 
provide at least 82% power to detect a risk difference of 13% in the proportion of good outcome from 
EVD+alteplase treatment compared to control, assuming a 22% proportion of good outcome among controls.  
The conjectured risk difference and good outcome rate under control were based on extrapolating from the 
previously completed Phase II CLEAR studies, which recorded baseline IVH clot volume and location (for ICH) 
and 30-day mRS outcomes.6 To do this, models were first fit using the data from these studies, and then used 
for simulating hypothetical trials at sample size 500 as described in section 2g of the supplemental appendix. 
 
We present data in three groups: the planned intention-to-treat (ITT) primary efficacy analyses of functional 
outcome; additional mRS efficacy analyses including other mRS analyses of various cut points, and secondary 
analyses of case fatality, clot removal, and ICU care; and safety. Adjusted analyses are indicated in Table S1. 
The primary and key secondary analyses were designated in 2008, at the start of the trial.  
 
ITT Efficacy Analysis: The primary aim was to assess clinical efficacy of EVD+alteplase by estimating the 
difference in the proportion of centrally-adjudicated mRS scores, dichotomised as ≤3 vs. >3, at 180 days. We 
estimated the average benefit comparing treatment vs. control, using the ITT principle. Specifically, we 
estimated the difference between the probability of 180-day mRS ≤3, referred to as a good outcome, 
comparing alteplase vs. saline. In accordance with the literature on covariate-adaptive randomised designs, 
the estimate of the adjusted treatment effect was based upon a weighted average of the difference in 
proportions for each of the six strata defined by the possible baseline combinations for covariates used in 
randomization: IVH volume and location. Weights were set proportional to the number in each stratum (pooled 
across arms). The 95% confidence interval, estimated by the percentile method for the average treatment 
effect, was computed by the nonparametric bootstrap method, such that the covariate-adaptive design is 
adhered to in each resampled (i.e., bootstrap replicated) data set. Multivariable logistic regression models were 
used to estimate the conditional effect of treatment on good mRS outcome for baseline variables.  
 
Secondary and Post-hoc Efficacy Analysis: Planned secondary efficacy analyses: 1) The Kaplan-Meier 
time-to-event analysis was used to estimate the survival functions and the log-rank test was used to compare 
8 
the survival by treatment. 2) A logistic model relating clot removed to mRS 0-3 proportion was used 
(Supplemental Table S2). These models were informed by univariate regression and well established clinical 
and epidemiologic considerations of the important prognostic factors of age, initial Glasgow Coma Scale (GCS) 
score (scores range from 3 to 15, with lower scores indicating reduced levels of consciousness), IVH size as a 
continuous variable, and the results of the planned intervention, clot removal. 3) Intensity of ICU management 
by treatment type was compared via Chi square or Fisher’s exact test, as appropriate. Results of planned 
analyses of key demographic subgroups for heterogeneity of treatment effect: IVH and ICH size, location, 
GCS, age, gender, and race are presented.  
 
Post hoc analyses were undertaken for two unexpected but clinically important findings: 1) when the number of 
subjects in mRS 5 category at 180 days was inspected for disproportion, a treatment comparison was made. 2) 
When inspection of protocol associated clot removal showed that alteplase achieved the hypothesised 
differential removal for subjects with IVH volume >20mL but not in the group with<20mL, subgroup by 
treatment group was undertaken. Interaction terms for treatment by baseline IVH stability volume at 20mL were 
considered. No correction for multiplicity was applied, as secondary analyses were considered hypothesis 
generating.   
 
Safety Analysis: The safety aim of the trial was to achieve near total clot dissolution without procedure-related 
safety events endangering subjects beyond the risks associated with intensive medical treatment.20 Analyses 
tested the null hypothesis that use of alteplase is safe for the treatment of IVH, relative to standard care of EVD 
alone under pre-specified thresholds for 30-day case fatality (40%), symptomatic rebleeding (25%), and 
bacterial brain infection (20%). We tested these three thresholds and all safety event rates as interim analyses 
after 100, 175, 250, and 350 subjects were enrolled and then for the full 500 over 180 days with Fisher’s exact 
test. The overall occurrence rate of serious adverse events (SAEs) was tested between the two treatment 
groups. 
 
Clot Removal Analysis: End of treatment (EOT) was defined as 24 hours after the last dose.18 Additionally, 
area under the curve (AUC) of the IVH time course from stability to EOT was calculated using the trapezoidal 
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rule to quantify clot removal over time. AUC values were normalised by the time elapsed from stability to EOT 
to account for variability in treatment times. Logistic and Cox regression analyses were done to evaluate the 
relationship between IVH removal, represented by the normalised AUC of IVH clot on mRS ≤ 3, and 180-day 
case fatality, respectively, after adjustment for ICH clot location, age, ICH volume at stability and randomization 
GCS.  
 
All analyses were conducted using two-sided tests with a Type I error rate of 0.05, performed using the 
statistical packages STATA 13.0 or higher (STATA Corp, College Station, TX) and R version 3.2 (R 
Foundation for Statistical Computing, Vienna, Austria). All data are presented as median [IQR: inter quartile 
range], unless otherwise specified.  
 
Role of the Funding Source: The principal investigator (DFH) conceived, organized and executed this trial.  
He had full access to all study data and had final responsibility for the decision to submit for publication. The 
sponsor NIH/NINDS provided input regarding the study design during the grant review process and the 
NIH/NINDS-appointed DSMB provided the same during active recruitment. The NIH/NINDS-appointed DSMB 
and Genentech, Inc. approved the decision to submit the paper for publication.  
 
Results 
 
Subjects: Between September, 2009 and January, 2015, 500 patients were randomised, with the last subject 
completing follow-up in January, 2016 (Fig. 1). The trial completed with 180-day follow-up data available for 
analysis from 246/251 and 245/249 subjects in the alteplase and placebo groups, respectively. Admission 
demographics and clinical severity factors are shown in Table 1 and were similar between groups. Subjects 
arrived at hospital within 1.5 [0.8, 3.5] hours of ictus and underwent a CT by 2.3 [1.4, 4.9] hours. ICH clot 
location was thalamus 59%, 32% other; and 9% primary IVH (no identifiable ICH). The baseline IVH and ICH 
sizes were 21.8 [12.7, 36.9] mL and 7.9 [2.5, 15.0] mL, respectively. Baseline mean arterial pressure and ICP 
were similar by group. Subjects received first EVD at 7.5 [5.0, 12.0] hours and bleeding was determined stable 
by 43.5 [26.9, 57.9] hours post ictus.  
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Acute Protocol Period: Randomization occurred at 52.1 [39.1, 66.5] hours, with first treatment given 3.0 [1.7, 
5.5] hours later. Five [3, 8] alteplase and 12 [9, 12] saline doses were given. EOT occurred at 2.5 [1.8, 3.7] and 
4.7 [4.0, 5.1] days post randomization for alteplase and saline respectively. In the alteplase group, the 3rd and 
4th ventricles opened more rapidly (p<0.0001). Twenty percent of all subjects achieved 80% removal of IVH, 
10% saline and 30% alteplase. Overall, 27% of subjects received two EVDs (dual catheters), one in each 
lateral ventricle. During treatment, most subjects (78%) experienced at least one ICP reading ≥20mmHg. 
Cerebral perfusion pressure (CPP) <70 mmHg occurred in 62% of subjects despite continuous EVD drainage; 
the proportion of CPP compromise was 2% less in the alteplase arm (see Table 1). Permanent ventriculo-
peritoneal shunts were placed in 18% of subjects. 
 
Primary Efficacy Outcomes: Retention to day 180 was 98%. The primary ITT analysis comparing arms by 
mRS ≤3 outcome was 48% for alteplase and 45% for saline (RR (95% CI)=1.06 (0.88, 128), p = 0.554) (Fig. 2 
and Table 2). The difference in good outcome (alteplase – saline) adjusted for IVH size and thalamic ICH was 
3.5% (RR (95% CI)=1.08 (0.90, 1.29), p=0.420), not significantly different from zero. A single subject received 
alteplase after completion of 12 doses of saline (crossover). A subsequent sensitivity analysis was performed 
with this subject moved to the active treatment arm. The primary results did not change. 
 
Secondary Outcomes and Safety: The mRS 6 (death) category showed a 50% decrease in the odds of being 
dead (mRS 6) for alteplase versus saline (Adjusted OR (95% CI) = 0.49 (0.37, 0.81), p = 0.001) (Table 3). No 
effect of hospital site was demonstrated for the primary mRS 0-3 outcome. (See Supplemental Table S1.) 
Estimated Kaplan-Meier survival probabilities were greater throughout 180 days of follow-up for the alteplase 
group (cumulative case fatality: 18% vs. 29%; p=0.006) (Fig. 3). Safety parameters favoured alteplase: 
bacterial ventriculitis (7% vs. 12%; RR (95% CI)=0.55 (0.31, 0.97), p=0.048) and SAEs (49% vs. 63%; RR 
(95% CI)=0.77 (0.66, 0.91), p=0.002). The frequency of symptomatic bleeding was similar between groups (2% 
in both arms; RR (95% CI)=1.21 (0.37, 3.91), p = 0.771). Table S1 in the supplemental appendix shows the 
primary, secondary and safety outcomes. Table 4 shows the safety profile by group and by the Medical 
Dictionary for Regulatory Activities (MedDRA) body system classifications. 
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A post-hoc analysis of the mRS 5 (i.e., bedbound) category shows a greater proportion in the alteplase group 
(17% vs. 9%; RR (95% CI)=1.99 (1.22, 3.26), p =0.005). Other post-hoc analyses demonstrated no difference 
in the proportion of subjects in a vegetative state, measured by the eGOS scale (3% in both groups; RR (95% 
CI)=1.33 (0.47, 3.78), p =0.787) nor for subjects surviving in long-term care facilities (alteplase 14% vs. saline 
12%; RR (95% CI)=1.18 (0.74, 1.88), p =0.479) (see Fig. 2 and Table S2). Neither Barthel index nor EuroQol 
Visual Analog Scale (EQ-VAS; self-reported, quality of life scale with scores ranging from 0-worst to 100-best 
imaginable health state) was different between groups (see Table S1). 
 
Clot Removal: Removal of clot varied widely, dependent on number and location of EVDs and number of 
alteplase doses. Thirty percent (30%) of the alteplase group and 10% of the saline group achieved the 80% 
removal endpoint. The planned secondary analysis relating mRS to the amount and timing of clot removal in all 
subjects demonstrated a significant relation between clot removal (per clot remaining (mL), as measured by 
normalised AUC) and both mRS ≤3 (AOR (95% CI)=0.96 (0.94, 0.97); p <0.0001) and case fatality (AHR (95% 
CI) of death per mL of time-weighted clot volume remaining = 1.03 (1.02, 1.04); p <0.0001), adjusted for age, 
thalamic ICH location, stability ICH volume, and randomised GCS (see Supplemental Table S3). The results of 
the subgroup analyses pre-specified in the protocol are shown in Supplemental Figure S1. No p values for 
interaction were significant.  
 
Discussion 
 
In the CLEAR III trial, irrigation of the ventricles with alteplase via a routine EVD did not improve functional 
outcomes in patients with IVH. Analyses of our secondary outcome measures, 180 day case fatality was 
significantly lower in the alteplase group, but the majority of these survivors ended up with severe disability 
(i.e., mRS4,5 or eGOS lower and upper significant disability). Clot removal analyses showed a correlation 
between amount of removal and improved mRS ≤3. Alteplase appears safe when compared to saline. These 
findings suggest possible value to the concept of removing greater amounts of IVH volume. On the face of the 
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current evidence, however, alteplase at the dose of 1 mg every 8 hours cannot be recommended as an 
intervention to improve functional outcome in patients with IVH.  
 
There are limitations to this trial. This was the first Phase III IVH thrombolysis trial and evidence-based 
standards for subject selection and treatment endpoint did not exist. Current guidelines do not mandate the 
use, number, or location of EVD catheters, which are important factors influencing the amount of IVH removed. 
Routine practice produced good adherence to EVD safety, and opening of the midline ventricles occurred; but, 
poor adherence to removal of >80% IVH. This lack of adherence may have limited the stringency of the test of 
our hypothesis. Not all severity factors are known, so imbalances in severity could have existed. For example, 
nonspecific factors (e.g., type and extent of ICU care) could have been different between the treatment arms 
and influenced outcomes. For ICU care this does not seem likely, as subject severity, “withdrawal of care,” and 
ICU care were similar between groups. CLEAR III was a small sample of current clinical practice taken from 
the most aggressive end of the treatment spectrum: those subjects whose physicians utilised EVDs. The 
control intervention represents an aggressive level of care not always offered to every subject with IVH. The 
baseline mortality and good functional outcomes observed in the CLEAR III controls was greater than in our 
prior study6 or in the expected levels from the general population (where low frequencies of EVD use are 
coupled with very high reliance on medical care as the sole supportive intervention for IVH).2,3,6,7,9 Only 
convenience sample data exists for outcomes of medically managed subjects thus our knowledge about risk 
and benefit for the intervention in the general population is limited. Another possible limitation is that the 
CLEAR III sample might not represent a true general IVH population, rather a milder or more severe 
population. Evaluations of the general population of IVH, concurrently performed, have demographics and 
severity factors matching CLEAR III. They show full population estimates of mortality (40%-60%) and low good 
functional outcome (10%-30%) suggesting less intense therapies may not produce as many benefits.2,5 Finally, 
the main outcome measure: mRS 0-3 vs. 4-6 proportion is only one measure of disability. Further research will 
be needed to clarify the divergent picture within the more severe disability segments of mRS and eGOS.21 If 
survival comes at the cost of living with unacceptable impairment, this or any treatment could be seen as 
limited in value.   
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Potential to improve practice is evident with the findings that CPP/ICP are not always controlled by a single 
EVD routinely placed into the anatomically largest pool of cerebrospinal fluid or least bloody site. This is a 
starting point for investigating multiple catheters where clot is large, bilateral, trapping the ventricle, or creating 
a local mass effect. Placing a second catheter near or into the largest portion of the clot leads to greater and 
more rapid removal22 and possibly greater clinical benefit. The precise clinical definitions for the at-risk 
population will need to be tested in a surgically-standardised trial setting.23 The signal of benefit from greater 
clot removal and the low percentage of subjects achieving 80% removal raise the possibility that benefit of 
alteplase may be possible if greater clot removal could be achieved and, if it is achieved, more rapidly. As 
CLEAR III did not demonstrate improved rates of good functional recovery with alteplase rather than saline, 
future investigation will need improved surgical placement of catheters to achieve effective clot reduction more 
frequently and more rapidly. A possible solution is an adaptively-designed, efficacy-to-effectiveness trial24 that 
demonstrates a better clot removal protocol can be integrated into routine stroke care and tests for influence 
on function, disability and case fatality.   
 
Panel: Research in Context 
 
Evidence before this study: A literature search was done from January 1, 1950 until November 1, 2015 on 
PubMed with the terms: IVH, IVH AND ICH, IVH AND TPA, IVH AND thrombolytic, IVH AND cross 
sectional, and IVH AND treatment. Search filters for "adult" and "human subjects" publications were 
applied.  Meta-analysis of case series, one small multisite trial, and single-site convenience samples suggest 
mortality and perhaps functional impairment can be mitigated via enhanced clearance of the IVH through 
thrombolysis. Prior to and after the Clot Lysis: Evaluating Accelerated Resolution of IVH Phase III (CLEAR III) 
trial, when caring for patients with a small ICH and large IVH, clinicians have no class 1 evidence regarding the 
safety and effectiveness of IVH thrombolysis.  
 
Added value of this study: CLEAR III is a randomised, double-blinded study designed to provide a test of the 
combination of extraventricular drainage (EVD) and low dose thrombolytic as a method of removing IVH and 
improving functional outcomes. This multisite study is the first to prospectively collect several objective 
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functional performance (modified Rankin Scale [mRS] and extended Glasgow Outcome Scale [eGOS]) as well 
as patient-based (Euro –QoL [EQ], Stroke Impact Scale [SIS]) measures of satisfaction. Medical care in the 
intensive care unit (ICU) was standardised and assessed rigorously. Data were prospectively defined and 
collected in a uniform manner and monitored thoroughly providing evidence of type, intensity and duration of 
ICU care required. Precise measurement of IVH size occurred in this trial possibly improving estimates of 
severity and treatment performance. The results of CLEAR III provide a robust estimate of the proportion of 
mRS 0-3 (approximately 45% to 48%) that occurs, if subjects are supported until the EVD is no longer needed. 
This led to an adjusted (IVH size and thalamic location) estimate of treatment effect of 3.5% (95% CI -4%, 
12%). This effect size was not different between alteplase and saline treatment plans, though case fatality did 
differ. The absolute proportion of mRS 0-3 found in all CLEAR III subjects compares favourably to the 
untreated subjects in the literature. The study provides detailed evidence that a protocoled approach to remove 
IVH with alteplase is safe and that the 3rd and 4th ventricles open sooner if alteplase is utilized.  A legitimate 
concern could be raised about greater infection rates due to frequent injections of alteplase or saline in the 
EVD, however a comparison of infection rate in CLEAR is in the same range as that reported in a meta-
analysis of infections from published EVD series where injections were not performed. The data presented 
characterise substantial variations in current EVD-related neurosurgical practice. They demonstrate usefulness 
of the measures of initial severity (Glasgow Coma Scale [GCS], location, and ICH/IVH size) and the elements 
of treatment needed for precise characterization of prognosis in the aggressively treated IVH patient. The sub-
group analysis suggests increased focus on larger IVH and earlier treatment times is appropriate. 
 
Implications of all the available evidence: The trial was neutral on primary outcome of functional improvement. 
Therefore we do not think practice should change. Other post hoc results are consistent with the hypothesis 
that removal saves lives and possibly improves function. The issue of survival with disability is now well 
defined by our primary results and other measures of disability. The secondary results leave open a possible 
role of IVH volume reduction as a biomarker for treatment, with better outcomes more likely achieved with 
enhanced IVH clearance, particularly in subjects with larger initial IVH volume. The results are consistent with 
prior convenience reports and meta-analyses that good functional outcome can occur in up to 50% of treated 
subjects. The data provide a sound basis to critically redefine short-term neurosurgical and ICU management 
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around the task of volume removal. A trial testing these more objective goals is needed, if we are to be 
assured that aggressive removal of IVH is safe and can predictably produce increased independent function 
and decreased case fatality. Current information suggests as many as 25% of ICHs have large IVH.  How 
many of these patients receive care and would be eligible for treatment is not known.  An estimate of the full 
benefit of intervention will require a combined epidemiological and RCT intervention approach that randomises 
available subjects and collects information about usual care controls. A novel trial would provide a 
standardised surgical task, treat subjects more rapidly and require greater care team adherence to the removal 
of large amounts of the IVH, not just removal of enough blood clot to open the 3rd and 4th ventricles. Sharing 
the full results of CLEAR III is likely to stimulate further investigations of a worldwide problem that is serious, 
growing, and could be treatable.  
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Disclosures of Interest.  
16 
After funding of the trial by the United States National Institutes of Health, Genentech provided drug at no cost. 
This is not a regulatory study sponsored by Genentech. There has been no other scientific input from other 
companies or entities.  
 
• H Adams reports grants from Johns Hopkins University, during the conduct of the study. 
• S Ansari reports grants from National Institute of Neurological Disorders and Stroke, during the conduct of 
the study; personal fees from BARD MEDICAL, outside of the submitted work. 
• I Awad reports grants from NIH/NINDS, during the conduct of the study. 
• C Thompson reports grants from National Institute of Neurological Disorders and Stroke, during the 
conduct of the study.  
• B Gregson reports grants from Johns Hopkins University (CLEAR III NIH grant), during the conduct of the 
study; grants from National Institute of Health Research (UK) HTA, outside the submitted work. 
• D Hanley reports grants from NIH/NINDS, during the conduct of the study; grants and personal fees from 
EKOS Corp, grants and personal fees from Brainscope, personal fees from Rand Corp, personal fees from 
medico-Legal, outside the submitted work. 
• M Harrigan reports grants from NIH, during the conduct of the study. 
• K Lane reports grants from NINDS, during the conduct of the study.  
• K Lees reports personal fees from Boehringer Ingelheim, outside the submitted work. 
• S Mayo reports grants from NIH/NINDS, during the conduct of the study; personal fees from Johns Hopkins 
University, outside the submitted work. 
• N McBee reports grants from National Institute of Neurological Disorders and Stroke, during the conduct of 
the study. 
• AD Mendelow reports grants from NIH, during the conduct of the study; non-financial support from Director 
of Newcastle Neurosurgery Foundation Ltd, personal fees from Advisor to Stryker and Draeger, outside the 
submitted work. 
• WA Mould reports grants from NINDS, during the conduct of the study. 
• J Muschelli reports grants from T32AG000247 NIA Training Grant, during the conduct of the study. 
• E Sugar reports grants from NIH/NINDS, during the conduct of the study. 
17 
• G Yenokyan reports grants from National Institute of Neurological Disorders and Stroke, during the conduct 
of the study; personal fees from The RAND Corporation, Health Advisory Services, outside the submitted 
work. 
• W Ziai reports personal fees from HeadSense Medical, Inc., outside the submitted work. 
 
The following authors have no conflicts of interest to disclose: 
O Adeoye, EF Aldrich, J Betz, K Butcher, J Carhuapoma, JL Caron, J Dawson, M Diener-West, D Gandhi, S 
Harnof, J Jallo, S Janis, S John, C Kase, P Keyl, D LeDoux, G Lopez, M Rosenblum, R Thompson, S Tuhrim, 
N Ullman, D Wright, and M Zuccarello. 
 
    
Acknowledgements. We wish to thank the CLEAR III patients and their families and the CLEAR III 
investigators and coordinators who provided and cared for them. We thank the Johns Hopkins University Brain 
Injury Outcomes (BIOS) Coordinating Center staff and site managers Bing Cao, Amanda Bistran-Hall, Tracey 
Hartmann and Noeleen Ostapkovich, the Reading Center readers, Timothy Morgan, Saman Nekoovaght-Tak, 
Hasan Ali, Vikram Madan, Alexandra Baker and Krissia Rivera Perla, and Coordinating Center Pharmacists, 
Janet Mighty and Esther Jeon; the University of Chicago Surgical Center managers, Agnieszka Stadnik, 
Jennifer Jaffe, and Michael Jesselson; Emissary International’s Sarah Lenington, Nicki Karlen, and Carolyn 
Koenig for monitoring management; Prelude Dynamics for developing the data management and 
randomization systems; the Newcastle Neurosurgical Foundation and Mawdsleys-Brooks for supporting the 
trial in the European Union; the University of Glasgow outcomes assessors and translators and Robertson 
Centre for Biostatistics programmers; the Johns Hopkins Bloomberg School of Public Health Biostatistics 
Department data managers, Rachel Dlugash, Carol Thompson, Malathi Ram, Gwendolyn Clemens, Andre 
Hackman, and Jennifer Houser, Ryan Majkowski and Maningbe Kieta for their project management and 
technical editing. We thank the NIH-appointed DSMB Bob S. Carter, MD, PhD (Chairman), Kyra J. Becker, 
MD, James C. Torner, MS, PhD, and Alex B. Valadka, MD for their guidance and oversight of the safety of the 
trial participants. We also thank the FDA Orphan Products Development program for supporting a high-risk 
idea that became a program of investigation. CLEAR III was supported by the grant 5U01 NS062851-05, 
18 
awarded to Dr. Daniel Hanley from the National Institutes of Health (NIH), National Institute of Neurological 
Disorders and Stroke (NINDS).  
 
Disclosures. Dr. Daniel F. Hanley was awarded significant research support of grants number R01NS046309, 
5U01 NS062851-05, and 5U01 NS080824-02.  
 
References 
 
1. Hanley DF. Intraventricular hemorrhage severity factor and treatment target in spontaneous intracerebral 
hemorrhage. Stroke 2009; 40(4): 1533-8. 
2. Hansen BM, Morgan TC, Betz J, et al. Intraventricular Extension of Supratentorial Intracerebral 
Hemorrhage: The Modified Graeb Scale Improves Outcome Prediction in Lund Stroke Register. 
Neuroepidemiology 2015; 46(1): 43-50. 
3. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of 
outcome in supratentorial intracerebral hemorrhage. Critical Care Medicine 1999; 27(3): 617-21. 
4. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral 
hemorrhage. New England Journal of Medicine 2001; 344(19): 1450-60. 
5. Moradiya Y, Murthy SB, Newman-Toker DE, Hanley DF, Ziai WC. Intraventricular Thrombolysis in 
Intracerebral Hemorrhage Requiring Ventriculostomy A Decade-Long Real-World Experience. Stroke 2014; 
45(9): 2629-35. 
6. Naff N, Williams MA, Keyl PM, et al. Low-Dose Recombinant Tissue-Type Plasminogen Activator 
Enhances Clot Resolution in Brain Hemorrhage The Intraventricular Hemorrhage Thrombolysis Trial. 
Stroke 2011; 42(11): 3009-16. 
7. Gaberel T, Magheru C, Parienti J-J, Huttner HB, Vivien D, Emery E. Intraventricular Fibrinolysis Versus 
External Ventricular Drainage Alone in Intraventricular Hemorrhage A Meta-Analysis. Stroke 2011; 42(10): 
2776-81. 
8. Nieuwkamp DJ, de Gans K, Rinkel GJ, Algra A. Treatment and outcome of severe intraventricular 
extension in patients with subarachnoid or intracerebral hemorrhage: a systematic review of the literature. 
Journal of Neurology 2000; 247(2): 117-21. 
9. Staykov D, Bardutzky J, Huttner HB, Schwab S. Intraventricular fibrinolysis for intracerebral hemorrhage 
with severe ventricular involvement. Neurocritical Care 2011; 15(1): 194-209. 
10. Ziai WC, Muschelli J, Thompson CB, et al. Factors affecting clot lysis rates in patients with spontaneous 
intraventricular hemorrhage. Stroke 2012; 43(5): 1234-9. 
11. MIS+rtPA for ICH Evacuation (MISTIE). 
12. Josephson CB, White PM, Krishan A, Al‐Shahi Salman R. Computed tomography angiography or magnetic 
resonance angiography for detection of intracranial vascular malformations in patients with intracerebral 
haemorrhage. The Cochrane Library 2014. 
13. Ziai WC, Tuhrim S, Lane K, et al. A multicenter, randomized, double‐blinded, placebo‐controlled phase III 
study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III). 
International Journal of Stroke 2014; 9(4): 536-42. 
14. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the 
controlled clinical trial. Biometrics 1975: 103-15. 
15. Weir CJ, Lees KR. Comparison of stratification and adaptive methods for treatment allocation in an acute 
stroke clinical trial. Statistics in Medicine 2003; 22(5): 705-26. 
16. Morgenstern L, Hemphill 3rd J, Anderson C, et al. American Heart Association Stroke Council and Council 
on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a 
guideline for healthcare professionals from the American Heart Association/American Stroke Association. 
Stroke 2010; 41(9): 2108-29. 
19 
17. Broderick J, Connolly S, Feldmann E, et al. American Stroke Association Stroke Council; American Heart 
Association/American Stroke Association High Blood Pressure Research Council; Quality of Care and 
Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous 
intracerebral hemorrhage in adults: 2007 update: a guideline from the American heart 
association/American stroke association stroke council, high blood pressure research council, and the 
quality of care and outcomes in research interdisciplinary working group. Circulation 2007; 116(16): e391-
413. 
18. Mould WA, Carhuapoma JR, Muschelli J, et al. Minimally invasive surgery plus recombinant tissue-type 
plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke 
2013; 44(3): 627-34. 
19. Morgan TC, Dawson J, Spengler D, et al. The modified Graeb score an enhanced tool for intraventricular 
hemorrhage measurement and prediction of functional outcome. Stroke 2013; 44(3): 635-41. 
20. Mattle HP, Raabe A. CLEAR Intraventricular Hemorrhage More Than a Glimmer of Hope. Stroke 2011; 
42(11): 2999-3000. 
21. TEASDALE GM, PETTIGREW LE, Wilson JL, MURRAY G, JENNETT B. Analyzing outcome of treatment 
of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. Journal 
of Neurotrauma 1998; 15(8): 587-97. 
22. Hinson HE, Melnychuk E, Muschelli J, Hanley DF, Awad IA, Ziai WC. Drainage efficiency with dual versus 
single catheters in severe intraventricular hemorrhage. Neurocritical Care 2012; 16(3): 399-405. 
23. Vespa PM, Martin N, Zuccarello M, Awad I, Hanley DF. Surgical trials in intracerebral hemorrhage. Stroke 
2013; 44(6 suppl 1): S79-S82. 
24. Selker HP, Oye KA, Eichler HG, et al. A proposal for integrated efficacy-to-effectiveness (E2E) clinical 
trials. Clinical Pharmacology and Therapeutics 2014; 95(2): 147-53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
Table Notes and Figure Legends  
 
Table Notes 
 
Table 1. Demographic and Baseline Subject Characteristics by Group.  
 
Table 2. Treatment Variables by Group. Additional Outcome Variable Data are Included as Table S4 in the 
Supplementary Materials. 
 
Table 3. mRS Score Frequencies for the 30, 180, and 365 Day Time Points. The 180-Day Data Represent the 
Primary, Unadjusted Outcome. Corresponding eGOS Data for the Same Time Points Can Be Seen in 
Supplemental Table S3. In the alteplase group, one subject who was initially thought to be lost to follow-up at 
day 30 was located and evaluated at day 180. 
 
Table 4. SAEs by treatment group. This listing shows fewer neurologic, respiratory, and sudden deaths (found 
in the MedDRA general disorders classification) in the alteplase group. This is consistent with the hypothesis 
that early removal of blood corrects a severe life threatening cerebral anatomic defect and possibly limits the 
structural brain injury as well as limits the effects of immobility on cardiorespiratory risks inherent with structural 
brain injury.   
 
Figures Legends 
 
Figure 1. CONSORT diagram. The CONSORT diagram summarizes the number of subjects that progressed 
through the enrollment, allocation, and follow-up periods of the trial. In the alteplase group, one subject who 
was initially thought to be lost to follow-up at day 30 was located and evaluated at day 180. 
 
Figure 2. Outcome dichotomies of mRS (left panel; scores range from 0 [no disability] to 6 [death]) and eGOS 
(right panel; scores range from 8-upper good recovery to 1-death) scores at 30 and 180 days by treatment. 
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The left panel blue lines indicate the differences in proportion of 180-day mRS ≤ 3 (45% in saline vs. 48% in 
alteplase; p=0.477) and deceased subjects (30% in saline vs. 19% in alteplase; p=0.09).  
 
Figure 3. Kaplan-Meier survival estimates with truncation at 193 days for late and missed 180-day visits 
(n=36), which corresponds to the longest “in-window” 180-day visit. Estimated survival probabilities were 
higher throughout 180 days of follow-up with alteplase compared to the saline group (p=0.006). 
 
Table 1 
 
 
Alteplase 
(N=249) 
Saline 
(N=251) 
Demographic variables   
Age in Years: Median [IQR] 59 [51, 66] 59 [51, 67] 
Gender: Female: no. (%) 105 (42) 117 (47) 
Race   
White: no. (%) 144 (58) 161 (64) 
African American: no. (%) 92 (37)  78 (31)  
American Indian or Alaskan Native: no. (%) 0 (0)  1 (<1)  
Other: no. (%) 13 (5) 11 (4) 
      Ethnicity: Hispanic/Latino: no. (%) 28 (11) 32 (13) 
Baseline variables   
Tobacco Use: no. (%) 73 (29) 59 (24) 
Cocaine Use: no. (%) 12 (5) 18 (7) 
Anticoagulated at Registration: no. (%) 20 (8) 29 (12) 
Antihypertensive Med Compliant (self-report): no. 
(%) 168 (67)  202 (80)  
Hyperlipidemia Med Compliant (self-report): no. (%) 240 (96)  245 (98)  
On Antiplatelet at Registration: no. (%) 56 (22) 72 (29) 
     Randomization MAP: Median [IQR] 96 [86, 106] 94 [86, 104] 
     Randomization GCS† Total: Median [IQR] 10 [7, 13] 9 [7, 12] 
     Randomization NIHSS: Median [IQR] (N=231) 19 [11, 32] 
(N=232) 
20 [11, 35] 
Stability CT (last CT prior to enrollment) 
IVH Volume (mL): Median [IQR] 
ICH Volume (mL): Median [IQR] 
21.2 [12.6, 36.1] 
8.2 [2.8, 15.2] 
22.4 [12.7, 39.1] 
7.2 [2.3, 14.7] 
Index Clot Location 
     Thalamus: no. (%) 149 (60) 144 (57) 
     Primary IVH: no. (%) 18 (7) 27 (11) 
Ictus to Hospital Arrival (hrs.): Median [IQR] 1.5 [0.8, 3.4] 1.5 [0.8, 3.6] 
Ictus to 1st CT (hrs.): Median [IQR] 2.3 [1.3, 4.6] 2.3 [1.4, 5.2] 
Ictus to 1st EVD (hrs.): Median [IQR] 7.0 [4.5, 11.8] 7.9 [5.0, 12.0] 
Ictus to Stability CT (hrs.): Median [IQR] 43.0 [25.4, 58.9] 44.0 [28.2, 57.0] 
Ictus to Randomization (hrs): Median [IQR] 51.8 [36.4, 65.8] 52.2 [41.2, 66.8]   
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Table 2  
 
 
Alteplase 
(N=249) 
Saline 
(N=251) p-value 
Treatment Variables    
Randomization to 1st Dose (hrs.): Median [IQR] 3.0 [1.7, 5.3] 3.1 [1.7, 5.7] 0.62 
Total number of Doses:  Median [IQR] 5 [3, 8] 12 [9, 12] <0.001 
Duration of Dosing (days): Median [IQR] 1 [1, 2] 4 [3, 4] <0.001 
Randomization to EOT (days): Median [IQR] 2.5 [1.8, 3.7] 4.7 [4.0, 5.1] <0.001 
EOT IVH Volume (mL): Median [IQR] 5.9 [1.9, 13.0] 11.5 [5.8, 23.1] <0.001 
Time to Open Ventricles (days): Median [IQR] 2 [2,3] 5 [3,7] <0.001 
ICP ≥20 mmHg: Mean proportion of events (mean 
of patient-specific proportions) 9.8 10.2 0.45 
CPP <70 mmHg was lower with alteplase: no. (%) 644(7) 867(9) <0.001 
One or more ICP Therapy(ies): no. (%) 67 (27) 77 (31) 0.35 
Dual EVD Placed: no. (%) 66 (27) 71 (28) 0.66 
Day 0-180 Bacterial Ventriculitis: no. (%) 17 (7) 31 (12) 0.05 
Symptomatic Bleeding ≤72 hr. post Last Dose: no. 
(%) 6 (2) 5 (2) 0.77 
SAEs: no. (%) 121 (49) 158 (63) 0.002 
Days in ICU: Median [IQR] 14 [11, 21] 15 [12, 22] 0.10 
Withdrawal of Care: no. (%)  27 (11) 30 (12) 0.70 
Ventilator Support: no. (%) 184 (74) 192 (76) 0.50 
Pressor/Inotrope use: no. (%) 60 (24) 63 (25) 0.79 
Ventriculoperitoneal Shunt: no. (%) 46 (18) 44 (18) 0.78 
†Scores on the Glasgow Coma Scale (GCS) range from 15 (fully conscious) to 3 (deep coma) 
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Table 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Visit and Treatment 
 30 days 180 days 
mRS 
Saline 
(n=249) 
Alteplase 
(n=245) 
Saline 
(n=245) 
Alteplase 
(n=246) 
0 4 1.61% 2 0.82% 11 4.49% 6 2.44% 
1 2 0.80% 4 1.63% 13 5.31% 19 7.72% 
2 7 2.81% 17 6.94% 31 12.65% 34 13.82% 
3 28 11.24% 27 11.02% 55 22.45% 58 23.58% 
4 46 18.47% 51 20.82% 41 16.73% 41 16.67% 
5 126 50.60% 122 49.80% 21 8.57% 42 17.07% 
6 36 14.46% 22 8.98% 73 29.80% 46 18.70% 
         
Total 249 100.00% 245 100.00% 245 100.00% 246 100.00% 
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Table 4 
 
Body System Alteplase Saline  
Blood and lymphatic disorders 0 1  
Cardiac disorders 7 14  
Gastrointestinal disorders 4 1  
General disorders and admin site conditions 22 34  
Hepatobiliary disorders 1 0  
Infections, non-neurologic 12 6  
Injury, poisoning and procedural complication 5 3  
Investigations (laboratory) 0 1  
Metabolism and nutrition disorders 0 1  
Musculoskeletal & connective tissue disorders 0 2  
Nervous system disorders 40 53  
Psychiatric disorders 1 2  
Renal and urinary disorders 2 2  
Respiratory, thoracic & mediastinal disorders 22 33  
Surgical and medical procedures 1 1  
Vascular disorders 4 4  
Total 121 158  
Percentage 48.6% 62.9% p=0.0016 
    
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
En
ro
llm
en
t 
Assessed for eligibility 
(n=10538) 
Prescreen failures (n=10038) 
-Inclusion criteria not met (n=8575) 
-Refused consent (n=132) 
-Other reasons (n=1331) 
Randomised (n=500) 
Active Treatment  
(EVD + alteplase) 
Placebo  
(EVD + normal saline) 
Active Treatment Arm 
Follow-up: 
Day 30 (n=247) 
Day 90 (n=246) 
Day 180 (n=246) 
Lost to Follow-Up (n=3) 
Withdrew (n=0) 
Total allocated to Placebo 
Arm (n=251) 
Total dosed (n=251) 
[Protocol violation (n=1): cross-
over dosing with commercial 
alteplase] 
 
Placebo Arm 
Follow-up: 
Day 30 (n=250) 
Day 90 (n=250) 
Day 180 (n=246) 
Lost to Follow-Up (n=5) 
Withdrew (n=0) 
 
Total allocated to Active 
Treatment Arm (n=249) 
Total dosed (n=249) 
[Protocol violation (n=1): 
additional dosing with 
commercial alteplase]  
 
A
llo
ca
tio
n 
Fo
llo
w
-U
p 
A
na
ly
ze
d 
Active Treatment Arm 
Analyzed: 
Day 30 (n=245) 
Day 180 (n=246) 
Placebo Arm  
Analyzed: 
Day 30 (n=249) 
Day 180 (n=245) 
Thrombolytic removal of intraventricular hemorrhage in treating severe stroke: Results of the CLEAR III trial, a 
randomised, controlled trial 
 
Hanley DF, et al. 
Supplemental Appendix 
 
 
Table of Contents 
 
1. List of sites, participating investigators and roles. .............................................................................................................. 2 
2. Methods............................................................................................................................................................................... 5 
2a. Methodological details of the treatment protocol .......................................................................................................... 5 
2b. Central adjudication of Rankin scale assessments (CARS) ............................................................................................ 7 
2c. Training, including eGOS and NIHSS .......................................................................................................................... 9 
2d. Severity Index Analysis .............................................................................................................................................. 10 
2e. Analysis of Interaction between Age and Mortality ................................................................................................... 11 
2f. Summary of Protocol Amendments ............................................................................................................................ 11 
2g. Monte Carlo simulations for sample size calculation ................................................................................................. 13 
3. Figures ........................................................................................................................................................................ 17 
3a. Figure S1. Subgroup analysis. ..................................................................................................................................... 17 
3b. Figure S2. CT images correlating to different IVH volumes. ..................................................................................... 18 
3c. Figure S3. Effect of treatment on mortality by age ..................................................................................................... 19 
3d. Figure S4. Relationship between mRS 0-3 and percent clot removed by IVH volume as determined at stability prior 
to randomization. .............................................................................................................................................................. 20 
4. Tables ......................................................................................................................................................................... 21 
4a. Table S1. Primary and secondary analyses descriptive listing and corresponding results. ......................................... 21 
4b. Table S2. eGOS score frequencies for the 30, 180, and 365 day time points. ............................................................ 26 
4c. Table S3. Univariable and Multivariable Analyses of Dichotomized mRS Modified Rankin Scale (mRS) Score at 
Day 180 (mRS 0-3 vs. 4-6) ............................................................................................................................................... 26 
4d. Table S4. Additional outcome variables by group. ..................................................................................................... 27 
4e. Table S5. Primary reason for exclusion by count and frequency. ............................................................................... 27 
4f. Table S6. Demographics for screen failures vs. enrolled subjects. ............................................................................. 28 
4g. Table S7. Proximate causes of death. ......................................................................................................................... 28 
4h. Table S9. Premorbid, historical modified Rankin Scale scores by treatment group. .................................................. 29 
4i. Table S10. Effect of treatment on mortality by age (data from Figure S4 in tabular format) ..................................... 29 
4j. Table S11. Summary of Key Primary and Secondary Analyses and Results from Supplemental Table S1. .............. 30 
5. REFERENCES .......................................................................................................................................................... 31 
 
 
 
Thrombolytic removal of intraventricular hemorrhage in treating severe stroke: Results of the CLEAR III trial, a randomised, controlled trial 
Hanley DF, et al. 
Supplemental Appendix 
 
Page 2 of 31 
 1. List of sites, participating investigators and roles. 
 
Site Name PI Lead Neurosurgeon  (if not PI) Study Coordinator 
Number of 
Subjects 
Enrolled 
Rush University Sayona John Lorenzo Munoz Josephine Volgi 25 
Chaim Sheba Medical Center Sagi Harnof  Nina Levhar 24 
University of Texas, Houston George Lopez, Nicole Gonzales P. Roc Chen Chad Tremont 21 
University of Maryland E. Francois Aldrich  Charlene Aldrich 19 
Johns Hopkins Hospital Wendy Ziai Judy Huang Mirinda White 18 
University of Alabama at 
Birmingham Mark Harrigan  Lisa Nelson 17 
Henry Ford Health System Panayiotis Varelas Donald Seyfried Kathleen Wilson 16 
University of Utah Safdar Ansari Richard Schmidt Stephen Chatwin 14 
NorthShore Long Island David LeDoux Salvatore Insinga Tim White 13 
Thomas Jefferson University 
Hospital Jack Jallo  Kara Pigott 13 
University of Texas, San Antonio Jean-Louis Caron  Esther Nanez 13 
University of Cincinnati Opeolu Adeoye Mario Zuccarello Lynn Money 12 
University of Iowa Harold Adams David Hasan Heena Olalde 12 
University of Heidelberg Julian Bösel Berk Orakcioglu Perdita Beck 10 
Case-Western Reserve University 
Hospital Alan Hoffer  Valerie Cwiklinski 9 
Maine Medical Center David B. Seder Jeff Florman Barbara McCrum 9 
University of Halle Katja Wartenberg Christian Strauss Doreen Herale 9 
University of Pittsburgh Medical 
Center Lawrence Wechsler Paul Gardner Kara Armbruster 9 
Allegheny General Hospital Ashis H. Tayal Khaled Aziz Melissa Tian 8 
Stanford University Chitra Venkatasubramanian Robert Dodd Madelleine Garcia 8 
UCLA Paul Vespa  Courtney Real 8 
University of Illinois at Chicago Fernando Testai  Maureen Hillmann 8 
University of Mainz Thomas Kerz Stefan Welschehold  8 
Vall d'Hebron University Hospital, 
Barcelona Fuat Arikan Ramon Torne 
Lourdes Exposito 
Mercedes Arrikas 8 
Cedars-Sinai Medical Center Asma Moheet  Felice Lin 7 
Hadassah Hebrew University 
Hospital Guy Rosenthal  Alex Furmanov 7 
Penn State Hershey Medical Center Kevin Cockroft  Deborah Hoffman 7 
University of Buffalo Jody Leonardo  Linda Bookhagen 7 
University of Southampton Hospital Diederik Bulters  Sophie Marlow Faith Vincent 7 
Bellvitge Hospital, Barcelona Alberto Torres Díaz  Meritxell Santos 6 
Columbia University Sachin Agarwal E. Sander Connolly Cristina Falo 6 
Sourasky Medical Center Tel Aviv Nevo Margalit Erez Nossek Carmit Ben Harosh 6 
University of Alberta Ken Butcher Max Findlay Leka Sivakumar 6 
University of South Florida David Decker Siverio Agazzi Denise Fife 6 
Georgetown University Mason Markowski  Courtney Hsieh 5 
Hartford Hospital Inam Kureshi  Sara Jasak 5 
Providence Stroke Center David Antezana Lisa Yanese Monica Rodriguez 5 
Springfield Neurological and Spine 
Institute H. Mark Crabtree  Jessica Ratcliff 5 
University of Debrecen Laszlo Csiba Sandor Szabo Katalin Szabó 5 
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Site Name PI Lead Neurosurgeon  (if not PI) Study Coordinator 
Number of 
Subjects 
Enrolled 
University of Leipzig Dominik Michalski Juergen Meixensberger Daniela Urban 5 
University of Pecs Laszlo Szapary Andras Buki Peter Csecsei 5 
Abington Memorial Hospital Qaisar A.Shah Steen J. Barrer Karin Jonczak 4 
Cooper University Hospital Thomas Mirsen Alan Turtz Andrew March 4 
Kansas University Medical Center Paul Camarata  Jason Gorup 4 
Mayo Clinic, Jacksonville William Freeman Ricardo Hanel Alexa Richie 4 
Medical University of South 
Carolina Christos Lazaridis  Marc Lapointe 4 
Ohio State University Medical 
Center Michel Torbey Ciaran Powers Nirav Patel 4 
SUNY Upstate Medical Center Julius Gene Latorre Eric Deshaies Iulia Movileanu 4 
University of Chicago Agnieszka Ardelt Issam Awad Cedric McKoy 4 
University of Tubingen Sven Poli Martin Schuhmann Julia Zeller 4 
Virginia Commonwealth University R. Scott Graham  Kelly Mathern 4 
Wake Forest University Kristi Tucker John Wilson Sandra Norona 4 
Yale University David Greer Murat Gunel Kimberly Kunze 4 
Montreal Neurological Institute at 
McGill University David Sinclair  Steven Salomon 3 
Mount Sinai Stanley Tuhrim  Ricardo Renvill 3 
Temple University Hospital Michael Weaver  Carol Von Hofen / Kathleen Hatala 3 
University of Erlangen Hagen Huttner Oliver Ganslandt Anja Schmidt 3 
University of Szeged Pal Barzo Zoltán Mencser Eniko Fako 3 
University of Texas, Southwestern, 
Dallas Christiana Hall Christopher Madden 
Katrina Van De 
Bruinhorst 3 
Vanderbilt Michael Froehler J Mocco Emily Gilchrist 3 
Hospital Sao Paulo Universidade 
Federal de Sao Paulo/UNIFESP Gisele Sampaio Silva Italo Caprano Suriano 
Dirceu Regis, Raul 
Valiente 2 
Hospital de Clinicas de Ribeirao 
Preto Pedro Telles Cougo Pinto Benedito Oscar Colli 
Rodrigo Barbosa 
Cerantola 2 
Hospital de la Santa Creu i Sant Pau, 
Barcelona Joan Marti-Fabregas Fernando Munoz Rebeca Marin Bueno 2 
Medical College of Wisconsin Ann Helms Wade Mueller Alicia Constanquay 2 
Saint Louis University Salvador Cruz-Flores Saleem Abdulrauf Susan Eller 2 
U Hosp, Inselspital, Bern Michael Reinert  Ralph Schaer 2 
University of Zurich Andreas Luft Betrand Actor Benjamin Hertler 2 
Mercy General Sacramento Kavian Shahi  Susan Croopnick 1 
New Jersey Neuroscience Institute at 
JFK Martin Gizzi  Charles Porbeni 1 
Newcastle General Hospital A D Mendelow Prokopios Panaretos, Francesco Vergani Barbara Gregson 1 
NorthShore Chicago Issam Awad  Jen Jaffe 1 
St. Luke's Brain and Stroke Institute, 
Kansas City Darren Lovick  Bridget Brion 1 
University of Southern California - 
Keck School of Medicine Benjamin Emanuel William Mack Doris Arroyo 1 
Albert Einstein Medical Center George Newman Mark Kotapka Nwosu Chukwunweike John 0 
Atlantic Neuroscience Institute Igor Ugorec  Zenona Lesko 0 
Boston University Medical Center James Holsapple  Thai Q. Vu 0 
Budapest - Honved Korhaz Peter Bazso  Attila Josvai 0 
Charite Universitatsmedizin in 
Berlin Eric Juttler   0 
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Site Name PI Lead Neurosurgeon  (if not PI) Study Coordinator 
Number of 
Subjects 
Enrolled 
Duke University Medical Center Michael Luke James  Ellen Bennett 0 
Hospital Sao Jose, Joinville Alexandre Luiz Longo Andre Sanches Pitzschk Juliana Antunes Safanelli 0 
Hospital Universitario Clementino 
Fraga Filho Jorge Marcondes de Souza  Marco Oliveira Py 0 
Hospital de Clinicas de Porto Alegre Sheila Cristina Ouriques Martins Apio C. Martins Antunes Natacha Fleck 0 
Hospital de Pronto Socorro de Porto 
Alegre Marcelo Kern 
Rogerrio Symanski da 
Cunha Susana Maria Endres 0 
InterCoastal Medical Center Mauricio Concha Robert Knego Jeanette Bryant 0 
London University Health Sciences 
Centre Mel Boulton  Robert Mayer 0 
Loyola University Medical Center Michael Schneck Hazem M. Ahmed Linda Chadwick 0 
Massachusetts General Hospital Christopher Ogilvy  Michael T Phillips 0 
Mayo Clinic Arizona Maria Aguilar Richard Zimmerman Patricia O'Donnell 0 
Puerto Rico Medical Center Fernando Santiago Ricardo Brau Ingrid Rodriguez 0 
Rambam Medical Center Menashe Zaaroor Leon Levi Efrat Velblum 0 
Ruan Neurology Clinic and Research 
Center Michael Jacoby Robert Hirschl Sheryl Inman 0 
Salford Royal NHS Foundation 
Trust Hiren Patel John Kitchton Victoria OLoughlin 0 
Swedish Medical Center David Newell  Jeannie Steed 0 
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2. Methods 
 
2a. Methodological details of the treatment protocol  
 
Eligibility Criteria: 
 
Inclusion Criteria 
 
1. Age 18-80. 
2. Symptom onset less than 24 hrs prior to diagnostic CT scan. 
3. Spontaneous ICH ≤ 30 cc and IVH obstructing 3rd and/or 4th ventricles. 
4. ICH clot stability: ICH must be ≤ 30 cc on initial presentation and not exceed 35 cc on subsequent pre-randomization stability 
scans. A CT scan performed 6 hours or more after IVC placement must be stable (difference is ≤ 5 cc) compared to the most 
previous CT scan as determined by the (AxBxC)/2 method.  
Temporary Criterion: If the clot is not stable (i.e., difference is > 5 cc), a repeat CT scan must be performed at least 
12 hours later and compared to the most previous CT scan. Investigator may continue to screen every 12 hours up to 
72 hours for the initial bleeding to stabilize, as long as the subject is able to be randomized within 72 hours of time 
of diagnostic CT scan and the clot remains ≤ 35 cc. If the size stabilizes (i.e., enlargement ≤ 5 cc between 2 
sequential CT scans) and remains ≤ 35 cc, the patient is eligible.  
5. IVH clot stability: The width of the lateral ventricle most compromised by blood clot must not increase by > 2 mm, allowing for 
movement of blood under influence of gravity.  
Temporary Criterion: If the clot is not stable (i.e., difference is > 2 mm), a repeat CT scan must be performed at least 
12 hours later and compared to the most previous CT scan. Investigator may continue to screen up to 72 hours for 
the initial bleeding to stabilize, as long as the subject is able to be randomized within 72 hours of time of diagnostic 
CT scan. If the size stabilizes (i.e., enlargement ≤ 2mm between 2 sequential CT scans), the patient is eligible. 
6. Catheter tract bleeding must be less than or equal to 5 cc on CT scan for stability.  
Temporary criterion: If a catheter tract hemorrhage is present on the CT scan done 6 hours after IVC placement and 
is > 5 cc or > 5 mm, obtain a repeat CT scan 12 hours later. This includes any bleeding at the entry site or along the 
catheter tract that is 5 mm in diameter seen on any CT slice or is 5 mL on more than one CT slice. If the catheter 
tract hemorrhage further enlarges by > 5 cc or > 5 mm as compared to the most previous CT scan, the investigator 
may continue to screen by repeat CT scan every 12 hours for the bleeding to stabilize, as long as the subject is able 
to be randomized within 72 hours of time of diagnostic CT scan. If the size stabilizes (i.e., enlargement ≤ 5 cc or ≤ 5 
mm between 2 sequential CT scans), the patient is eligible. 
7. On stability CT scan, the 3rd and/or 4th ventricles are occluded with blood. 
8. All patients randomized will have had EVD placed, ideally using no more than 2 complete passes (including “soft passes” using 
the original trajectory), on an emergent basis as defined by the “standard of care” neurosurgical/critical care decisions of the 
managing physicians. If more than 2 passes are required for placement, additional stabilization of IVC site will be determined 
with a CT performed at 24 hours after IVC placement. 
Temporary criterion: If no IVC is in place at the time the patient is initially screened, the decision to place an IVC 
may occur after the patient is initially screened but an IVC must be in-place and stable at the time of 
randomization. 
9. Patients with primary IVH are eligible (i.e. with ICH=0). 
10. SBP < 200 mmHg sustained for the 6 h before drug administration (closest to randomization). 
Temporary criterion: Blood pressure inclusion criteria not met when the patient is screened: Most vital signs are 
stabilized within the time window for enrollment. 
11. No test article may be administered until at least 12 hours after symptom onset. 
12. Able to randomize within 72 h of CT scan diagnosing IVH (provided the time of symptom onset to diagnostic CT does not exceed 
24 h).  
Temporary criterion: The 72 hour limit may be extended with approval from the Coordinating Center to allow for 
clot stability (ICH, IVH, catheter tract), INR stability, or other valid reason. 
13. Historical Rankin of 0 or 1. 
 
Exclusion Criteria 
 
1. Suspected (unless ruled out by angiogram or MRA/MRI) or untreated ruptured cerebral aneurysm, ruptured intracranial AVM, or 
tumor. Treatment of an existing aneurysm or AVM must have occurred at least 3 months before the current onset.   
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Temporary criterion: This is especially important in primary IVH, when no ICH source is found. CT angiogram, 
angiogram, MRA/MRI, or general diagnostic study (prior to confirming patient eligibility in the protocol) is 
standard of care to rule out underlying etiology. If the CT angiogram, angiogram or MRA/MRI is negative, the 
patient is eligible. The PI must document rationale if imaging is not done. 
2. Presence of a choroid plexus vascular malformation or Moyamoya disease.   
3. Clotting disorders. Subjects requiring long-term anti-coagulation are excluded. 
Temporary criterion:  Reversing anticoagulation will be permitted where long-term anticoagulation is not 
required.  
4. Use of Dabigatran, Apixaban, and/or Rivaroxaban (or a medication from the same medication class) prior to symptom onset. 
5. Platelet count < 100,000, INR > 1.4. 
Temporary criterion: Low platelet counts etc. on admission can normalize within 24 hours as can an INR 
normalize to < 1.4. 
6. Pregnancy (positive serum or urine pregnancy test). 
7. Infratentorial hemorrhage  
8. Thalamic bleeds with apparent midbrain extension with third nerve palsy or dilated and non-reactive pupils. Other (supranuclear) 
gaze abnormalities are not an exclusion.  Note: Patients with a posterior fossa ICH or cerebellar hematomas are ineligible. 
9. SAH at clinical presentation (an angiogram (angiogram, CTA, MRA/MRI) must be obtained when the diagnostic CT scan shows 
SAH or any hematoma location or appearance not strongly associated with hypertension.  If the angiogram or other imaging does 
not detect a bleeding source to account for the hemorrhage, the patient is eligible for the study.) Subsequent appearance of cortical 
SAH secondary to clot lysis is not a dosing endpoint. 
Temporary criterion: An angiogram must be obtained when the diagnostic CT scan demonstrates subarachnoid 
hemorrhage or any hematoma location suggestive of aneurysm or appearing not strongly associated with 
hypertension.  If the angiogram/imaging does not demonstrate a bleeding source that accounts for the hemorrhage, 
the patient is eligible for the study.   
10. ICH/IVH enlargement that cannot be stabilized in the treatment time window.   
Temporary criterion: ICH enlargement during the 6-hour stabilization period (6 hours after IVC placement): It is 
permitted to screen up to 72 hours after diagnostic scan. If the ICH clot size stabilizes (i.e., enlarges no more than 
5 cc) and does not exceed 35 cc (an ICH clot size of 35 cc allows for stabilization of a 5cc expansion for those 
patients at the upper limit of the ICH clot size limit), the patient is eligible. 
11. Ongoing internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts. (Patient with 
prior bleeding that is clinically stable for 12 h or more without any coagulopathy or bleeding disorder is eligible).  
12. Multi-focal, superficial bleeding, observed at multiple vascular puncture and access sites (e.g., venous cutdowns, arterial 
punctures) or site of recent surgical intervention. 
13. Prior enrollment in the study. 
14. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were 
initiated. Subjects who are not expected to survive to the day 180 visit due to co-morbidities and/or are DNR/DNI status prior to 
randomization are excluded. 
Temporary criterion: Although these situations are often irreversible, under other conditions, change can occur 
over 24 hours. 
15. Planned or simultaneous participation (between screening and Day-30) in another interventional medical investigation or clinical 
trial. Patients involved in observational, natural history, and/or epidemiological studies not involving an intervention are eligible.  
16. No subject or legal representative to give written informed consent. 
 
 
Stability Protocol: The risks of initial hematoma growth/instability were managed by use of a stability protocol combining 
normalization of coagulation parameters, blood pressure (BP) management, and repeat CT assessment of clot size measured using the 
ABC/2 method.1 Six or more hours after the diagnostic CT, a stability CT was performed to ensure that the ICH clot was not 
expanding by >5 mL and that qualitative expansion in IVH had not occurred, providing image demonstration of a safe starting point 
for clot reduction therapy, defined as the absence of ongoing bleeding before randomization and initiation of test article. The CT could 
be repeated every six hours until the clot stabilized or just before the 72-hour eligibility window closed, whichever came first. In 
addition, a magnetic resonance image (MRI) or CT angiography (CTA) was encouraged as vascular pathology screening; an 
angiogram was encouraged where equivocal findings were noted on vascular pathology screening.2 An INR ≤1.4, a platelet count > 
100,000, and BP stability < 200 mm Hg were required prior to randomization.3,4   
 
EVD management: The Surgical Center located at the University of Chicago actively reviewed all catheter placements and 
monitored clot removal assessments, catheter discontinuation protocols, and evaluated the safety and efficacy of the surgical 
procedure.1 The Surgical Center recommended pull-back and/or replacement of catheters that were sub-optimally placed within the 
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ventricular system as well as placement of a second, concurrent catheter ipsilateral or contralateral to the most affected side for 
optimal test article delivery. Recommendations were not mandatory.  
 
Test article administration protocol: Eligible subjects were adaptively randomized to receive intraventricular injections of either 
normal saline or alteplase. Local pharmacists were notified to prepare the assigned “test article” such that the clinicians remained blind 
to assignment. Intraventricular alteplase administrations of 1.0 mg in 1 mL were given every 8 hours, up to 12 doses, or until an 
endpoint was reached. All doses were followed by a 3 mL flush of preservative-free normal saline. After each assigned dose, the 
system was closed for one hour to allow drug-clot interaction, and then opened to allow for gravitational drainage. Trial-defined 
clinical endpoints included, opening of 3rd and 4th ventricles, mitigation of IVH-related mass effect, 80% reduction of clot volume 
measured on the stability CT, reaching a maximum of 12 doses or occurrence of a clinically significant bleeding event, defined as a 
clot enlargement accompanied by sustained drop of more than two points on the Glasgow Coma Scale (GCS) motor score with CT-
demonstrated ICH enlargement. CT scans were subsequently obtained every 24 hours until dosing was complete to evaluate safety and 
drainage. Test article administration was performed under standard conditions to maintain sterile environment and cranial 
compartment euvolemia. Procedural training was mandatory. Selection of the dosing endpoint was determined on a subject-by-subject 
basis at each site. 
 
Image analysis: To optimize accuracy and minimize investigator bias, clot volumes were analyzed by a core laboratory utilizing 
semi-automated segmentation and Hounsfield thresholds.5 This was performed using OsiriX software (v.4.1, Pixmeo; Geneva, 
Switzerland) on DICOM images of each subject’s stability and treatment scans. This approach has been validated for accuracy and 
inter-rater reliability.6 Core lab values were utilized in all analyses. Core lab defined location as either thalamus or other (lobar, 
putamen, caudate). 
 
Prohibited medications: The administration via any brain catheter of any thrombolytic agent (other than the study agent administered 
per protocol) was prohibited. Clogged catheters were flushed with normal saline. Antithrombotic and antiplatelet agents were 
prohibited prior to the day 30 follow-up visit. Enoxaparin at therapeutic doses ≥1,0 mg/kg subcutaneously every 12 hours was 
prohibited during the 12-month study period following randomization.  
 
2b. Central adjudication of Rankin scale assessments (CARS) 
 
CARS Infrastructure 
 
The Central Adjudication of Rankin Scale assessments (CARS) system is a secure web based portal designed specifically for the 
upload and central adjudication of video recorded mRS endpoints in the CLEAR-III trial (https://www.glasgowctu.org/CLEAR3). The 
CARS portal was developed by staff of the Institute of Cardiovascular and Medical Sciences and technical support of the Robertson 
Centre for Biostatistics, both within the University of Glasgow. It provides fully validated backend study databases for collection of 
all Rankin scores and review decisions taken from endpoint committee members, where applicable.   
 
The CARS systems are fully documented and incorporate a complete audit trail from upload to score.  CARS is fully compliant with 
relevant GCP guidelines and was developed and validated in accordance with Computerised Systems for Clinical Research guidelines 
and 21 CRF Part 11 – Electronic Records and Electronic Signatures.  Dates and times are recorded at both local and central database 
levels and are compliant with ISO 8601: 1988 (E) (Data elements and interchange formats – Information interchange – Representation 
of dates and times).  The web pages are only accessible using secure socket layer (SSL) communication, which utilises a validation 
certificate created for a particular server within a specific domain.  This enables authentication from the server to the user’s browser 
and encrypts all traffic between their local computer and the authenticated host server.  The web server is secured by VeriSign, the BT 
Trust Services Global Server Certificate program and is firewall-protected. 
 
Training in Modified Rankin Scale Assessment: All CLEAR-III assessors (local and central) underwent training and certification in 
mRS assessment using an online training resource. Study staff were also provided with bespoke instruction for use of the CARS 
system in the trial, including guidance on mRS scoring and on conducting interviews for central review. 
 
CARS Staff: The CARS system was overseen by a team at the University of Glasgow comprising an outcomes manager who oversaw 
the day to day running of the system, trained and experienced adjudicators, and a team of translators for relevant non-English 
languages.  
 
Communication between CARS System and Trial Management Systems: The CARS portal was integrated with the CLEAR-III 
EDC managed by VISION during initial trial set up, such that investigators were able to upload assessments via the main trial 
management system in a secure manner. This simultaneously automated transfer of information (such as patient identification number, 
visit date, visit site and assessment language) to the CARS system. The same connection allowed the CARS system to return status 
Thrombolytic removal of intraventricular hemorrhage in treating severe stroke: Results of the CLEAR III trial, a randomised, controlled trial 
Hanley DF, et al. 
Supplemental Appendix 
 
Page 8 of 31 
reports including ‘successful upload’ to the trial management system and ultimately to return the completed mRS score. Automated 
status updates were relayed to both the trial management system and the CARS team both on attempt and on completion of upload, to 
allow monitoring of video uploads and quick identification of any problem.  All communications maintained blinding of the CLEAR-
III coordinating center staff. 
 
Addressing Technical difficulties: A technical support team based at the Robertson Centre of Biostatistics within the University of 
Glasgow was responsible for the maintenance of the CARS portal and responding to any issues that arose. Team members were 
available via telephone or email.  
 
Performing and Uploading Modified Rankin Scale Assessments 
 
Recording of the Modified Rankin Scale Assessment: A portable digital video camera with an in-built microphone was used to 
record the mRS interview. Video cameras were supplied through the CLEAR-III management team. Examples of models used are the 
FLIP Mino (CISCO systems, San Jose US) and the PIXPRO SPZ1 (Eastman Kodak Company, Rochester US). The assessor was 
directed to sit opposite the participant and beside (or holding) the camera, out of view. The camera was to be positioned a suitable 
distance from the participant so that the recording captured the participant’s face and trunk. The videos were recorded in standard 
definition at 60fps ensuring a reasonable file size for upload. The CARS system handled a diverse range of commonly used file types 
such as .mp4, .wmv, .avi, .mov, .mpg, .mts and .m4v. 
 
Upload of the Modified Rankin Scale Assessment: Upload was performed via the trial management system (VISION EDC), 
requiring trial staff only to have a single log in. The USB connections were used to connect the camera to a computer and to transfer 
files for upload. Users monitored progress of the upload via a status bar and received an automated notification upon successful 
upload. 
 
Central Adjudication of Modified Rankin Scale Assessments 
 
Initial Review for Technical Adequacy, Anonymity and Masking of Treatment Allocation: In the CLEAR-III trial an outcomes 
manager received an automated email upon successful upload of an assessment. The system would then block further upload of 
assessments for this participant. Upon receipt of successful upload notification, the outcomes manager reviewed the assessment for 
quality and maintenance of blinding. If the assessment was clearly inadequate, either in terms of technical factors (such as no audio, 
no patient visible, incorrect patient study identity or visit number) or was lacking in sufficient information to begin the scoring 
process, it was labelled with a status of ‘technically inadequate.’ This would prompt an automated message to the local investigator 
that further information or a replacement assessment was required. The CARS system would update the EDC and then allow further 
uploads to be submitted. Minor editing of assessments could be performed by the outcomes manager at this stage to preserve 
anonymity, masking of treatment allocation or to conceal details of the local score; such editing was tracked for audit purposes.  
 
Translation of Non-English Language Clips: Non-English language assessments were sent for translation to a bilingual native 
speaker of that language, with experience in the use of the mRS. Translations were performed using a digital recording device and the 
ensuing audio file was uploaded directly to the CARS system, where the audio file was then merged (overdubbed) with the original 
video of the mRS assessment. Both the native language and translated assessment were available for review by the assigned 
adjudicators. Upon successful upload of a translation the outcomes manager again assessed the translations to ensure blinding and 
protection of patient confidentiality.  
 
Review and Scoring of Assessments 
 
Assessments were assigned to CARS reviewers, who would be contacted via an automated email containing a direct link to the 
assigned assessment in the CARS system. Reviewers each had unique login details to permit tracking of workload and quality. They 
could access the video clips via either desktop or portable devices, to allow timely review and scoring. Reviewers recorded their 
chosen score within the CARS portal while the relevant video recording was on screen, and were also asked to record comments to 
justify their choice of score, that would be helpful in the event of subsequent committee discussion. 
 
In the CLEAR-III trial, the scoring algorithm accepted as final any score that agreed between the local and first central rater. However, 
if there was a discrepancy between the local and first CARS score, then the assessment proceeded to committee review, for which 3 
further independent reviews of this assessment were performed. Once 4 scores had been independently assigned, the committee of 
these raters discussed the assessment and reached a consensus on final score. This consensus score was entered to the CARS portal by 
the committee chairman and the score was automatically returned to the VISION EDC. Tracking of the stages is possible. 
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Quality Control and Ongoing Training  
We monitored inter-rater agreement for mRS scores, allowing us to optimize assessment guidance or to identify any rater who may 
benefit from additional training. We provided feedback to investigators at all sites and arranged refresher training in mRS assessment 
during the CLEAR-III trial via webinar sessions, including example video assessments.  
 
CARS staff 
 
Adjudicators: 
Jen Alexander (Queen Elizabeth University Hospital Glasgow, UK), Jesse Dawson (University of Glasgow, UK), Peter Higgins 
(University of Glasgow, UK), Kennedy Lees (University of Glasgow, UK), Kate McArthur (University of Glasgow, UK), Terry 
Quinn (University of Glasgow, UK), Matthew Walters (University of Glasgow, UK), Alastair Wilson (University of Glasgow, UK) 
 
Translators: 
Sukainah Al Alshaikh (University of Glasgow, UK), Samantha Alvarez-Madrazo (University of Glasgow, UK), Péter Bukovics 
(University of Pecs, Hungary), Laila Day (University of Glasgow, UK), Catarina Fonseca (Universidade de Lisboa, Portugal), 
Benedikt Frank (University Hospital Essen, Germany), Nora Gonzalez (University of Glasgow, UK), Karim Hajjar (University 
Hospital Essen, Germany), Kerrick Hesse (University of Glasgow, UK), Nicki Karlen (Emissary LLC, Israel), Kitti Kovacs 
(University of Debrecen, Hungary), Ananada Mirchindani (University of Glasgow, UK), Guillaume Turc (Sainte-Anne Hospital Paris, 
France) 
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2c. Training, including eGOS and NIHSS 
 
Training modules were prepared for key personnel at the enrolling sites. Key personnel were defined as the principal investigator, 
coordinator, pharmacist and others designated to perform data collection, drug preparation, and drug administration.  
 
Initial Training ensured that all site personnel were properly trained concerning FDA regulations, ICH guidelines, and trial policies 
and procedures. During the investigator start up meeting, the first training module included design and methods of the trial, the 
importance of integrity in acute and follow-up data collection, the need for data security, study organization, performance and 
compliance, and actual treatment procedures, and coordinators were required to work through sample VISION/Prelude EDC screens. 
The training modules were incorporated into the MOP. The CC worked with the site investigators to continuously identify and correct 
problems of compliance, data collection, outcomes assessment and data processing. 
 
The following is the list of mandatory investigator/coordinator training modules: 
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Enrolling Site Training Events – New Personnel Method Site Initiation 
Annual 
Recertification 
Refresher 
Design and methods of the trial 
Importance of integrity in data collection 
Need for data security 
Study organization 
Performance and compliance 
Treatment procedures 
Current Study Results 
Power point presentation    
Human Subjects 
HIPAA 
Ethics 
Conflicts of Interest 
On-line training    
Electronic Data Entry On-line training     
Sample Data Set Hands on training    
Web Site Access On-line training    
Modified Rankin Scale Certification Video training and test    
NIHSS Certification Video training and test    
eGOS, SIS, EQ, QOL, PBSI Power point presentation    
CT Stability Training On-line training and certification    
Drug Administration Certification Video training and test    
IVC Placement Certification Power point presentation    
Graeb Scoring Tutorial Power-point presentation    
Ventricular Opening Endpoints Power-point presentation    
Pharmacy Procedures Power-point presentation    
Recruitment and Consent  Power-point presentation    
AE and SAE Reporting Power-point presentation    
Protocol Deviations  Power-point presentation    
Study Progress and Procedural Changes Power-point presentation    
Protocol Test Web-based Certification test    
 
Extended GOS (eGOS): Site personnel were trained on eGOS administration technique using a MS PowerPoint module developed by 
the CC. The eGOS was obtained by local, trained personnel as part of the follow-up procedures at days 30, 180, and 365. Proxy 
interview was utilized if the subject scored <18 on the Mini-Mental Status Examination. The eGOS was first recorded onto a paper 
bedside worksheet as source documentation and then entered into the VISION EDC system. These date were monitored by the QA 
Monitor for transcription errors and consistency among all other outcomes assessments. 
 
NIHSS: Site personnel were instructed to utilize existing online NIHSS certification websites to obtain certification and then upload 
documentation of successful course completion to the VISION EDC electronic master file. Certification was obtained prior to the site 
initiation meeting with recertification required annually. NIHSS was captured if done by the clinical care team as close to the time of 
presentation as possible, and then done by a certified examiner at randomization, day 7, and again at follow-up days 30, 180, and 365. 
The NIHSS was the only outcomes assessment done at day 7. The interview was first recorded onto a paper bedside worksheet as 
source documentation and then entered into the VISION EDC system. These date were monitored by the QA Monitor for transcription 
errors and consistency among all other outcomes assessments. 
2d. Severity Index Analysis 
 
As an initial step in developing our severity index for predicting mRS (0-3), categories for well established “explanatory” variables:  
age, GCS at randomization, and stability ICH were created according to the distribution of the data for each variable. Two or more 
categories were combined if equally predictive of mRS (0-3), based on univariate logistic regression models. IVH and ICH location 
were set to their pre-specified values (i.e., < 20 mL, >= 20 – 50 mL, and > 50 mL, and thalamic and non-thalamic, respectively). The 
final categories considered were:  Age (<=50 yrs, 50- <60 yrs, 60 – <65 yrs, 65 - <70 yrs, and >=70 yrs), GCS (<= 9, 10-12, and 13-
15), ICH (<= 8 mL, >8 – 15 mL, > 15 mL), IVH (< 20 mL, >=20 – 50 mL, > 50 mL), and ICH location (thalamic, non-thalamic). 
Next, a multivariable logistic regression was created that regressed the binary outcome of mRS <=3 vs. mRS >3 on these 5 predictors. 
(Gender was considered in this model, but was determined to be non-significant, and therefore dropped).  
 
Based on the coefficients of this model, the severity was created that weighed each category as follows: Severity Index = 1.0 *(1 if age 
>=50 and <60, 0 otherwise)  + 1.3*(1 if age >=60 and <65, 0 otherwise) + 1.85*(1 if age >=65 and <70, 0 otherwise) + 2.0*(1 if age 
>=70, 0 otherwise) + 1.7*(1 if GCS <=9, 0 otherwise) + 1.0*(1 if GCS =10-12, 0 otherwise) + 0.8*(1 if thalamic, 0 otherwise) + 
0.8*(1 if IVH >=20 and <=50, 0 otherwise) + 2.4*(1 if IVH >50, 0 otherwise) + 0.85*(1 if ICH >8 and <=15, 0 otherwise) + 2.0*(1 if 
ICH >15, 0 otherwise). This score gives a maximum possible value of 9.0; however the highest score seen in the data set was 8.85. A 
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score of 0 indicates the lowest severity (e.g., a patient with an age <=50 years, GCS >=13, IVH < 20 mL, ICH <=8 mL and non-
thalamic ICH).  
 
Regression of the odds of mRS (0-3) gives a decrease of approximately 63% in the odds of having a 180-day mRS <=3 for each one 
unit increase in the severity score, a result that is highly statistically significant (OR [95% CI] = 0.37 [0.31, 0.44], p < 0.001). 
Treatment assignment was not statistically significant once we controlled for severity by this index, a result that is consistent with that 
reported in Table S2 (Adj OR [95% CI] = 0.92 [0.59, 1.44], p = 0.716). In addition, there was no evidence of a treatment by severity 
interaction effect (p=0.973).  
 
However, clot removal as measured by normalized AUC (as a percent of stability IVH), was significant once we controlled for 
severity (Adj OR [95% CI] = 0.998 [0.997, 1.000], p = 0.037). Again there was no evidence of an AUC by severity interaction effect 
(p=0.773).  
 
A similar process was followed to create an index score to predict 180-day mortality. Categories of variables were slightly different 
than for the mRS (0-3) index, and thalamic location was not found to be predictive of mortality as compared to other ICH locations. 
The mortality score was created as follows: Mortality Index = 0.5 *(1 if age >=50 and <60, 0 otherwise)  + 0.6*(1 if age >=60 and 
<65, 0 otherwise) + 1.0*(1 if age >=65 and <70, 0 otherwise) + 1.4*(1 if age >=70, 0 otherwise) + 0.8*(1 if GCS <=7, 0 otherwise) + 
1.0*(1 if IVH >= 20 and < =50, 0 otherwise) + 1.7*(1 if IVH >50, 0 otherwise) + 0.9*(1 if ICH >15, 0 otherwise). This score gives a 
maximum possible value of 4.8, with the highest value seen in the data set of 4.8.  
 
Regression of the odds of death at 180 days indicates just over a two-and-half fold increase in the odds of death for each one unit 
increase in the mortality score, a result that is highly statistically significant (OR [95% CI] = 2.74 [2.15, 3.49], p < 0.001). Treatment 
assignment was highly statistically significant once we controlled for the mortality index, a result that is consistent with our reported 
survival analyses (Adj OR [95% CI] = 2.01 [1.26, 3.20], p = 0.003, severity adjusted odds of death at 180 days for saline vs. 
alteplase). This effect was consistent across all levels of the mortality severity index.    
 
2e. Analysis of Interaction between Age and Mortality 
 
As shown in Figure S3 and Table S10, analyses of the interaction between age and mortality lend weight to our conclusion that 
alteplase reduces 180-day mortality compared to the saline-treated patients.  
  
In our assessment of this possible interaction on mortality, we considered 1) the risk ratio (RR) of death across 5 strata of age (<50 yr, 
50 - <60 yr, 60 - <65 yr, 65- <70 yr, and >70 yr), and 2) created a Cox model that incorporated an age (continuous variable) by 
treatment interaction.  
 
We found that the RR varied from 0.42 – 0.80 across all five age strata, giving a Mantel-Haenszel combined RR = 0.64. We then 
tested the null hypothesis for homogeneity across age strata (chi2 [deg =4] = 1.41, p= 0.842), the non-significant finding is concordant 
with the presence of consistent relative risk across all age strata (e.g. no heterogeneity of treatment effect across age strata). Similarly, 
the age by treatment interaction term in the Cox model with both the main effects of age and treatment is not statistically significant 
(HR interaction = 1.01, p = 0.665). This suggests the effect of alteplase on mortality is not modified by age. 
 
Therefore, based on these analyses, we concluded that the difference in mortality between treatment arms is consistent across every 
age strata, and there is no statistical evidence indicating an effect modification of age on the association between treatment and 
mortality. 
 
2f. Summary of Protocol Amendments 
 
v1.1 (8 Oct 2008) to v2.0 (15 Jun 2009) 
 
• Vital signs monitoring/data collection frequency changed from q1hr to q4hr. Vital signs monitoring/data collection schedule 
changed from days 1 through ICU discharge to days 1-7 with daily assessment of ICP management beginning on day 8 and 
continuing through IVC removal. ICP management data will be collected retrospectively at hospital discharge and will be used to 
monitor compliance with EVD management/weaning protocol. 
• Removed the GOS scale as an outcome scale. The GOS will now be computed from the extended GOS. 
• Added the EQ-5D to the day 90 and 270 telephone follow-up visits. 
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• The Mini-Mental State Exam will now be administered to everyone, not just to subjects with GCS<15 as previously written. 
• Exclusion criteria: 
o Added Moyamoya disease. 
o Lowered the acceptable INR from 1.7 to 1.3 for eligibility and for dosing. Also deleted PT as a determination of 
eligibility. Eligibility is now based on INR ≤1.3 and aPTT within normal limits.  
• Deleted daily laboratory assessments of PT, fibrinogen, plasminogen, d-dimer. Now only collecting daily serum WBC, Hct, 
platelet count, INR, aPTT as well as daily CSF labs. Plasminogen and fibrinogen will be assessed once prior to first dose. 
• Deleted IVC tip culture upon removal. 
• Specified that all quality monitoring of subject data will be done remotely. The VISION/Prelude EDC system will be used to 
query the data. Source documentation may remain identified. 
 
 
V2.0 (15 Jun 2009) to v3.0 (22 Mar 2011) 
 
• Incorporated adaptive randomization. 
• Added the Personal Health Utility Assessment Interview to the 180 day follow-up visit. 
• Inclusion criteria: 
o Changed the enrollment window from first dose within 72 hours of diagnostic CT to randomization within 72 hours of 
diagnostic CT. 
o Raised the acceptable INR from 1.3 to 1.4. 
• Permit use of heparin during the acute treatment period. 
• Increased stability period from 12 to 24 hours during dosing. 
 
 
V3.0 (22 Mar 2011) to v4.1 (17 Apr 2013) 
 
• Added exclusion of patients taking Dabigatran. 
• Allow the use of enoxaparin during dosing along with other low molecular weight heparins that are already considered Permitted 
Interventions. 
 
 
V4.1 (17 Apr 2013) to v4.2 (1 Jull 2013) 
 
• Added further exclusion from randomization of patients taking Apixaban, Rivaroxaban and similar medications in addition to 
Dabigatran. 
• Added prohibition of Apixaban and Rivaroxaban in addition to Dabigatran through day 30. 
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2g. Monte Carlo simulations for sample size calculation 
 
Power and sample size derivations were based on the 180-day outcomes, to yield minimum statistical power calculations. That is, the 
given sample size would have at least the reported power to observe a treatment difference at 180 days. Inclusion of additional data 
and information through the longitudinal analyses would serve to enhance model efficiency and thus increase power.  
 
2g.1. Statistical Power - Primary Endpoint 1 (Modified Rankin Scale ≤3 at 180 days). Statistical power for primary endpoint 1 was 
derived from Monte Carlo simulation studies based on the empirical relationships observed in the previous Safety, CLEAR A and 
CLEAR B studies. mRS outcomes were simulated from sequential conditional distributions based on the previously observed data in 
the Safety, CLEAR part A, and CLEAR part B (24 patients) studies as follows: 
F(mRS, site, rt_PA, IVH volume, ICH volume, ICH Clot Location)  
           =      F(mRS | site, rt_PA,   ivh_10cc,   ich_10cc,  location) 
                 * F(rt_PA | ivh_10cc,   ich_10cc,  location) 
                             * F(ivh_10cc |  ich_10cc,  location) 
                                               * F(ich_10cc | location) 
                                                                * F(location)  
 
Simulation data for power calculations was thus generated in five steps:  
 
Step 1: Simulate clot locations. Clot locations in the 88 patients from the Safety, CLEAR part A and part B studies were distributed 
as: Thalamus, n=41 (47%); Caudate\Putamen, n= 16 (18%), Other 
location, n=10 (11%), No Measurable Clot, n=21 (24%). We used 
this information to guide clot locations in a simulated sample of 
size N=500 by drawing from a multinomial distribution with 
related probabilities. For example, in simulation dataset 1, we drew 
clot locations of: Thalamus, n=246 (49%); Caudate\Putamen, n= 
134 (27%), Other location, n=57 (11%), No Measurable Clot, n=63 
(13%).  
 
Step 2: Simulate ICH volumes based on clot location. ICH 
volumes within the “No Measurable Clot” location were all 0cc. 
For the remaining clot locations, lognormal distributions of ICH 
volumes truncated at 30cc were used to account for design 
restrictions and skewness in the observed Safety, CLEAR A and 
CLEAR B ICH volumes. Calculated lognormal parameters (mean, 
standard deviation) were: Thalamus, (2.56, 0.73); 
Caudate\Putamen, (2.16, 0.86), other location, (1.42, 1.06). For our 
(N=500) simulation dataset 1, the resulting joint distribution of clot 
locations and ICH volumes is depicted in Figure 2g-1. 
 
Step 3: Simulate IVH volumes based on ICH and clot location. 
In the Thalamus location, a linear regression of IVH volume on 
ICH volume with estimated relationship E(IVH) = 23.81 + 
0.45(ICH), and residual standard deviation of 20.35 fit the data 
well.  For the Caudate\Putamen location, a linear regression of IVH volume on ICH volume with estimated relationship E(IVH) = 
57.51 + 0.15(ICH) and residual standard deviation of 39.48 was used.  For the Other location, the IVH-ICH relationship was inverse, 
with parameter estimates of E(IVH) = 49.84 – 0.83(ICH) and residual standard deviation of 22.34. In the “No Measurable Clot” 
location, there was no information to estimate an IVH-ICH relationship, and thus IVH volume was simulated under a Gaussian model 
using the observed sample mean and standard deviation values of (mn=68.76, sd=37.79). Joint plots of the IVH volume, ICH volume, 
and clot location relationships are shown in Figure 2g-2. 
 
Fig. 2g-1. Joint distribution of clot locations and ICH 
volumes 
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Step 4: Simulate the rt-PA assignment based on IVH & ICH 
volumes, and clot location. The study design incorporated simple 
random allocation for treatment assignment. Hence, simulated EVD 
+ rt-PA was a random coin flip with a 50% chance of receiving rt-
PA. 
 
Step 5: Simulate the mRankin outcomes based on the rt-PA 
assignment, IVH & ICH volumes and clot location. Parameter 
estimates for the categorical mRS outcomes observed in the Safety, 
CLEAR part A and part B studies were as follows: treatment effect: θ 
= 0.6 to 0.8 (i.e. odds-ratio of 1.8 to 2.2); IVH volume: b1 = -0.043; 
ICH volume b2 = -0.097; Clot Location: Thalamus: b3 = -0.83; 
Caudate\Putamen: b4 = 1.01; No Measurable Clot: b5 = -0.82.  For a 
control rate (p0) approximately = 0.20, intercepts a0 =  -0.1, a1 = 0.05, 
a2 = 0.25, a3 =  0.65, a4 =  2.90, a5 =  5.95 were used;  for a control 
rate approximately = 0.30, intercepts a0 =  -0.5, a1 = 0.2, a2 = 0.75, a3 
=  1.5, a4 =  3.04, a5 =  5.55 were used.  Additionally, site clustering 
or between-site heterogeneity was parameterized as a latent effect 
with standard deviation τ=.1 and .25, assuming approximately 50 
sites. These values led to probability curves as depicted in Figure 2g-
3, which shows the likelihood of attaining each mRS outcome across 
IVH volumes for the Thalamus clot location. The numbers directly 
above the probability curves denote the respective mRS score. Note 
that our observed data from the Safety and CLEAR part A study 
yields all seven probability curves shifted to the right under the EVD 
+ rt-PA intervention, yielding higher success probabilities for lower (better) mRS outcomes. Given a subject’s simulated clot location, 
ICH volume, IVH volume and treatment assignment, mRS outcome scores could then be drawn from a multinomial distribution with 
probabilities following these empirically observed relationships.  
  
If we use this technique to draw a sample of mRS outcomes of size N=500 (proposed trial size), we inherently simulate one possible 
outcome of the proposed trial. 
Following the five steps in this 
simulation procedure a large number 
of times, such as 1000, analyzing the 
resulting datasets each time and 
recording whether we obtain 
statistically significant treatment 
effect results at the 5% level leads to 
Monte Carlo estimates of the 
proposed trial’s power to detect a 
treatment difference. Using this 
machinery, a variety of simulation 
scenarios were examined to judge 
the sensitivity of power towards 
sample size (N=500, 600 & 700), 
effect size (odds-ratio = 1.8 to 2.2), 
control group outcome rates 
(placebo rates of good outcome 
mRS <3 = 20%, 30%), model choice 
(correctly specified vs. non-correctly specified model), and site clustering (between site heterogeneity parameterized as a latent effect 
with standard deviation τ =.10 and .25 [i.e. 14% and 36% of log-odds-ratio treatment effect theta =.7 , (OR = 2.0), respectively]). 
Figure 2g-4 shows the power across varying levels of sample size and treatment efficacy parameter theta=log(OR) with a between site 
heterogeneity parameter τ=.10, for both dichotomized outcomes mRS <3 and mRS <4. P0 represents the proportion of patients in the 
EVD + placebo group with good outcomes (mRS < 3 or mRS < 4). 
 
Figure 2g-3. Modified Rankin Score probabilities observed in the Safety and CLEAR Part 
A results used for Monte Carlo power study simulations. 
Thalamus:  EVD + placebo Thalamus: EVD plus rt-PA  
Fig. 2g-2. Joint plots of IVH, ICH volumes and clot 
location relationships  
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Hence, the proposed sample size of N=500 adequately 
powered the trial to detect treatment effects around our 
previously observed treatment effect; clot removal with 
EVD + rt-PA resulting in a doubling of the odds of having a 
better mRS outcome when controlling for IVH and ICH 
volume and clot location. This corresponded with being 
able to determine an absolute difference of 15% or more in 
the probability of better outcomes comparing EVD + rt-PA 
and EVD + placebo groups, as specified in our primary 
hypothesis. Given our experience in controlling rebleeding 
and maximizing clot removal in the more recent CLEAR A 
and B studies, we expected the previously observed 
measure of θ = 0.7 (OR = 2.0) to be a conservative estimate 
of the treatment effect.  
 
Additional simulations were performed to examine 
sensitivity towards effects of a potential latent patient-
severity factor based on an IVH volume > 60 cc.  Inclusion 
of this factor in the simulation methodology did not change 
the overall power results. 
 
 
In addition to the Monte Carlo simulations above, we investigated power 
for the primary endpoint 1 for a study designed to enroll a total of 500 
patients through standard rate comparison power formulae. The power 
available to detect various effect sizes is shown for ranges between 20% 
to 35% of the current EVD + placebo group achieving a good outcome 
(such as mRS score ≤ 3) calculated using the normal approximation with 
continuity correction for a two sample test of equality of proportions 
(Table 2g-1).  
 
2g.1.2. Statistical Power - Primary Endpoint 2 (Modified 
Rankin Scale as Ordinal Score at 180 days). Clot removal with EVD 
and treatment with low-dose rt-PA for IVH clot removal produces 
improved outcome(s) assessed by the ordinal mRS when compared to 
EVD + placebo (Fleiss, Statistical methods for rates and proportions, 
New York: John Wiley & Sons, Inc.; 1981). The power to detect 
difference between treatment groups may be enhanced by retaining the ordinal nature of the mRS, hence we expected greater than 
85% power as in the simulations detailed above. Binomial exact 95% confidence intervals for groups of 50, 125 and 250 patients for 
Table 2g-1. Power Available to Detect Specified Effect With Alpha = 
0.05 For Two Groups of Size 250 (Total of 500 patients)  
 Proportion with Good Outcome in the EVD + placebo  Management Group   
Effect size  
(Abs diff.) 20% 25% 30% 35% 
25% >.99 >.99 >.99 >.99 
20% >.99 >.99 >.99 >.99 
15% .96 .94 .92 .91 
14% .93 .91 .88 .87 
13% .89 .86 .84 .82 
12% .84 .80 .77 .75 
11% .78 .73 .70 .68 
10% .70 .65 .61 .59 
Table 2g-2. Confidence intervals for event rates  
Event 
Rate * 
95% Confidence Interval  
Around Event Rate for 
 50 patients 125 patients 250 patients 
.05 .013 -.165 .018 -.102 .025 -.082 
.10 .033 -.218 .056 -.171 .066 -.144 
.15 .072 -.291 .094 -.227 .106 -.198 
.20 .100 -.337 .134 -.281 .152 -.255 
.25 .146 -.403 .175 -.333 .196 -.306 
.30 .179 -.446 .225 -.393 .244 -.361 
.35 .229 -.508 .269 -.442 .289 -.411 
.40 .264 -.548 .313 -.491 .339 -.464 
.45 .318 -.607 .359 -.540 .385 -.512 
.50 .355 -.645 .413 -.595 .436 -.564 
* Or closest rate to this achievable with an integer number of events 
 
 
 
Figure 2g-4: Power curves from dichotomous mRS 
endpoints across varying levels of sample size and treatment 
effect [theta=log(OR)] for between site heterogeneity 
parameter τ=.10 (14% the effect size of the treatment efficacy 
at theta=.7 ). For N=500, power is greater than 80% for 
combinations of parameters near those observed in current 
studies (p0=.25, theta=.7). 
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event rates ranging from 0.05 to 0.50 are shown in Table 2g-2. In terms of detecting differences in adverse event rates between the two 
groups, the study had 80% power, or better, to detect an increase of 0.125 in the rate of any event among the rt-PA treated patients 
provided the rate of that event experienced by patients who received  EVD + placebo is at least 0.10. For example, if the bleeding or 
infection rate was 0.15 (15%) in the EVD + placebo group, the study had 80% power or better to detect a difference between the 
groups if the rate in the rt-PA group was 0.275 (27.5%) or higher.  
 
2g.1.3. Statistical Power - Primary Endpoint 3 (Modified Rankin Scale ≤4 at 180 days). EVD and treatment with low-dose 
rt-PA for IVH clot removal produces improved outcome(s) using an alternate mRS cutoff at 180 days of mRS < 4. Power for primary 
endpoint 3 was examined similarly to that for the primary endpoint 1. As in Figure 2g-4, there was greater than 80% power to detect 
mRS < 4 in all situations examined in the Monte Carlo simulations. 
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3. Figures 
 
3a. Figure S1. Subgroup analysis.  
 
Forest plot of interaction terms, adjusted for age, gender, thalamic ICH location, stability ICH, IVH volume, and GCS (mild=13-15; 
moderate=9-12; severe=3-8) at admission. The size of points indicates the relative sizes of the subgroups. Scores on the Glasgow 
Coma Scale (GCS) range from 15 (fully conscious) to 3 (deep coma). 
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3b. Figure S2. CT images correlating to different IVH volumes.  
 
Volumetric software (Osirix) was used to measure clot volume by outlining and totaling each region of interest (IVH, ICH, catheter 
tract, and other areas of bleeding. The images presented here are representative of the sub groups of IVH volume used for adaptive 
randomization (<20 mL, 20-50 mL, >50 mL). 
 
 
  
ICH: 1.31 cc IVH: 52.2 cc 
ICH: 7.17 cc IVH: 18.3 cc ICH: 0 cc IVH: 8.3 cc 
ICH: 6.3 cc IVH: 32.6 cc 
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3c. Figure S3. Effect of treatment on mortality by age 
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3d. Figure S4. Relationship between mRS 0-3 and percent clot removed by IVH volume as determined at stability prior to 
randomization. 
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4. Tables 
 
4a. Table S1. Primary and secondary analyses descriptive listing and corresponding results.   
 
 Analyses  Results Notes Interpretation 
Primary Outcomes     
1.1. 180 day mRS* (0-3)     
Univariate Treatment  Chi-Square Test  
Alt: 47.6%, Sal: 44.9%. Risk Diff (95% CI) = 2.7%  
(-6.2%, 11.5%), p = 0.554   
Adjusted for IVH/ Thalamus Wt-effect Across 6 Strata Risk Diff (95% CI) = 3.5% (-4.2%, 11.9%)   
Full Adjustment   Multivariable Logit Model 
Adj OR (95% CI) = 1.17 (0.74, 1.84),   p = 0.496. OR for 
mRS <= 3 v. > 3; Alt v. Sal. 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat) 
No difference  by random 
grp for mRS 0-3 
proportion 
     
1.2. mRS* as Ordinal Score Unadj Prop Odds Model  
OR (95% CI) = 0.81 (0.60, 1.11), p = 0.198. OR for mRS 
> K v. <= K; Alt v. Sal.  
Null hypothesis of prop odds rejected; 
chi2 p = 0.025*  
 Adjust Prop Odds Model 
Adj OR (95% CI) = 0.74 (0.53, 1.02), p = 0.068. Adj OR 
for mRS > K v. <= K; Alt v. Sal.  
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)*  
   
Null hypothesis of prop odds rejected; 
chi2 p = 0.018  
 
Unadj Gen Ordered Logit Model for 
Ordered Data 
OR (95% CI) = 0.90 (0.66, 1.24), p = 0.538. OR for mRS 
> K v. <= K if K = 1 - 4; Alt v. Sal.  
Prop Odds satisfied for mRS 0, 1 - 4 
assumed identical (chi 2 p=0.9967).* 
    
OR (95% CI) = 0.55 (0.37, 0.81), p = 0.003. OR for mRS 
> 5 v. <= 5; Alt v. Sal.  
 Prop Odds satisfied for mRS 0, 1 - 4 
assumed identical (chi 2 p=0.9967).* 
Mortality less with 
random assignment to 
alteplase 
 
Adjust Gen Ordered Logit Model #1 for 
Ordered Data 
Adj OR (95% CI) = 0.86 (0.62, 1.19), p = 0.379. Adj OR 
for mRS > K v. <= K if K = 1 - 4; Alt v. Sal.  Adj for Thal and  Stab IVH (cat)*  
    
Adj OR (95% CI) = 0.49 (0.32, 0.74), p = 0.001. Adj OR 
for mRS > 5 v. <= 5; Alt v. Sal.   Adj for Thal and  Stab IVH (cat)* 
Mortality less with 
random assignment to 
alteplase 
 
Adjust Gen Ordered Logit Model #2 for 
Ordered Data 
Adj OR (95% CI) = 0.89 (0.63, 1.25), p = 0.497. Adj OR 
for mRS > K v. <= K if K = 1 - 4; Alt v. Sal.  
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)*  
    
Adj OR (95% CI) = 0.44 (0.28, 0.71), p = 0.001. Adj OR 
for mRS > 5 v. <= 5; Alt v. Sal.  
 Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)* 
Mortality less with 
random assignment to 
alteplase 
     
1.3. 180 day mRS* (0-4)      
Univariate Treatment  Chi-Square Test  
Alt: 64.2%, Sal: 61.6%. Risk Diff (95% CI) = 2.6% (-
5.9%, 11.1%), p = 0.552   
Full Adjustment   Multivariable Logit Model 
Adj OR (95% CI) = 1.22 (0.79, 1.88),   p = 0.372. OR for 
mRS <= 3 v. > 3; Alt v. Sal. 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)  
     
1.4. Random Effects (mRS* 0-3) 
Random Effects Model w/ site as 
random effect 
OR (95% CI) = 1.11 (0.81, 1.53), p = 0.514.  OR for good 
outcome Alt v. Sal.  ICC = 1.3 X 10^-6 Unadjusted  
No differences of mRS 0-
3 attributable to site 
differences 
 
Adj Random Effects Model w/ site as 
random effect 
Adj OR (95% CI) = 1.17 (0.77, 1.78), p = 0.461. OR for 
good outcome Alt v. Sal. ICC = 2.2 X 10^-7 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)  
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 Analyses  Results Notes Interpretation 
1.5. Longitudinal (mRS* 0-3) 
Uadj GEE model (Logit  mRS (0-3) at 
30 and 180 days 
30 Days: OR (95% CI) = 1.34 (0.85, 2.12) p = 0.207; 180 
Days: OR (95% CI) = 1.10 (0.77, 1.57) p = 0.597  
No between grp 
differences mRS 0-3 over 
time 
 
Adj GEE model (Logit  mRS (0-3) at 30 
and 180 days 
30 Days: OR (95% CI) = 1.26 (0.75, 2.10) p = 0.384; 180 
Days: OR (95% CI) = 1.01 (0.62, 1.64) p = 0.964 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)  
     
 
 
Secondary Outcomes     
2.1 All-Cause Mortality - 180 days Log Rank Test Mortality - Alt: 18.5%, Sal: 29.1%. P = 0.0056   
Less mortality with 
random assignment to 
alteplase 
     
2.2. Clot Removal  AUC / Logit Model 
Adj OR (95% CI) = 0.96 (0.94, 0.97), p < 0.001. OR for 
mRS (0-3) per time-wt mL. 
Adj for Trt, Age, GCS, Thal, Stab 
ICH 
Greater clot removal 
associated with greater 
likelihood for mRS 0-3 
IVH by Trt Interaction Multivariable Logit Model 
IVH < 20 mL - Adj OR (95% CI) = 0.69 (0.35, 1.38), p = 
0.295. OR for mRS <= 3 Alt v. Sal.  
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)  
    
IVH >= 20 mL - Adj OR (95% CI) = 1.87 (1.02, 3.43), p 
= 0.044. OR for mRS <= 3 Alt v. Sal.    
Per protocol analysis: 
greater mRS 0-3 in key 
randomized subgroup 
with assignment to 
alteplase 
80% of Clot Removed Multivariable Logit Model 
Adj OR (95% CI) = 1.38 (0.82, 2.33), p = 0.226. OR for 
mSR (0-3) for >80% v. <= 80%  Clot Removed 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)  
85% of Clot Removed Multivariable Logit Model 
Adj OR (95% CI) = 1.91 (1.03, 3.55), p = 0.040. OR for 
mSR (0-3) for >85 % v. <= 85%  Clot Removed 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat) 
Threshold analysis- Post 
hoc- justified given 
finding of relationship to 
removal 
90% of Clot Removed Multivariable Logit Model 
Adj OR (95% CI) = 2.25 (1.10, 4.58), p = 0.026. OR for 
mSR (0-3) for >90% v. <= 90%  Clot Removed 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat) 
Threshold analysis- Post 
hoc- Justified  given 
finding of relationship to 
removal 
     
2.3. Critical Care Management 
Rank Sum for skewed data (instead of 
linear regression), Chi-Square Test (in 
place of univariate logistic model)    
Hosp Days   
Median (IQR) - Alt: 23 (17,31) days, Sal: 24 (16,31), p = 
0.771   
ICU Days  
Median (IQR) - Alt: 14 (11,21) days, Sal: 15 (12, 22), p = 
0.098 
Alt: 15 (12,22), Sal: 16 (13, 23), 
p=0.23  
     
Critical Care Complications     
ICP Management Generalized Linear Models 
Mean proportion of events of ICP >20mmHg – Alt: 9.8 
mmHg, Sal: 10.2 mmHg, p = 0.450 Mean of patient-specific proportions  
Mechanical ventilation  Alt: 73.9%, Sal: 76.5%, p=0.501   
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 Analyses  Results Notes Interpretation 
Pressors   Alt: 60%:Sal: 63%, p=0.795   
Use of Shunts   Alt: 18.5%, Sal: 17.5%, p=0.784   
        
All infections Day 30 (SR)  Alt: 48.2%, Sal: 50.6%, p=0.592   
pneumonia day 30  Alt: 26.1%, Sal: 32.7%, p=0.105   
All infections Day 180 (SR)  Alt: 49.8%, Sal: 56.2%, p=0.152   
     
2.4. 30-Day Mortality / Safety 
Fisher's Exact Test (was used instead of 
univariate logistic model due to small 
cell size)    
Mortality w/in 30 days   
Alt: 8.8%, Sal: 14.3%. Risk Diff (95% CI) = -5.5% (-
11.1%, 0.08%), p = 0.055 
Bar Plot in ISC Slides (Hanley Talk). 
Email 2/9/16   
Bacterial Brain Infections  
Alt: 6.8%, Sal: 10.4%. Risk Diff (95% CI) = -3.5% (-
8.4%, 1.4%), p = 0.202   
Systematic Bleeds w/ 72 hours  
Alt: 2.4%, Sal: 2.0%. Risk Diff (95% CI) = 0.42% (-
2.2%, 3.0%), p =0.771   
Systematic Bleeds w/ 30 days  
Alt: 3.6%, Sal: 3.2%. Risk Diff (95% CI) = 0.43% (-
2.8%, 3.6%), p =0.811   
     
2.5. AE / SAE 
Fisher's Exact Test (was used instead of 
univariate logistic model due to small 
cell size) 
Alt: 48.6%, Sal: 62.9%. Risk Diff (95% CI) = -14.4% (-
23.0%, -5.74%), p = 0.002  
Fewer subject with SAEs 
in the alteplase grp 
Brain infections day 180 (SR)   Alt: 7%, Sal: 12%, p=0.047   
Fewer brain infections at 
180 days in the alteplase 
grp  
     
2.6. Predictors of Mortality 
Unadjusted Cox Proportional Hazards 
Model HR (95% CI) = 0.59 (0.41, 0.86), p = 0.006; Alt v. Sal  
Model shows random 
assignment to alteplase 
associated with lower 
mortality 
 
Unadjusted Cox Proportional Hazards 
Model 
Adj HR (95% CI) = 0.58 (0.40, 0.85), p = 0.005; Alt v. 
Sal 
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat) 
Adjusted model shows 
random assignment to 
alteplase associated with 
lower mortality 
     
2.7. Sub-Group Analyses 
Chi-Square Test - Difference in mRS 0-3 
proportion    
Race (AA)  
AA - Alt: 54.4%, Sal: 48.0%. Risk Diff (95% CI) = 6.4% 
(-8.8%, 21.7%), p = 0.410 N = 165  
Race (White)  
White - Alt: 43.4%, Sal: 41.8%. Risk Diff (95% CI) = 
1.6% (-9.6%, 12.8%), p = 0.781 N = 301  
Gender(Female)  
Female - Alt: 47.6%, Sal: 45.6%. Risk Diff (95% CI) = 
2.0% (-11.3%, 15.2%), p = 0.773 N = 217  
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 Analyses  Results Notes Interpretation 
Gender (Male)  
Male - Alt: 47.6%, Sal: 44.3%. Risk Diff (95% CI) = 
3.2% (-8.5%, 15.1%), p = 0.587 N = 274  
Age (<= 65 yr)  
<= 65 - Alt: 53.6%, Sal: 52.1%. Risk Diff (95% CI) = 
1.5% (-9.0%, 12.1%), p = 0.775 N = 346  
Age (> 65 yr)  
> 65 - Alt: 31.3%, Sal: 29.5%. Risk Diff (95% CI) = 1.9% 
(-13.2%, 16.9%), p = 0.808 N = 145  
IVH (≤20 mL)  
< 20 - Alt: 55.1%, Sal: 58.3%. Risk Diff (95% CI) = -
3.3% (-16.5%, 9.9%), p = 0.625 N = 217  
IVH  (20 - 50mL)  
20 - 50 - Alt: 47.3%, Sal: 38.5%. Risk Diff (95% CI) = 
8.7% (-4.3%, 21.8%), p = 0.191 N = 219  
IVH (> 50 mL)  
> 50 - Alt: 18.5%, Sal: 17.9%. Risk Diff (95% CI) = 
0.66% (-19.7%, 21.1%), p = 0.949 N = 55  
Location (Thalamic)  
Thalamic - Alt: 38.8%, Sal: 37.4%. Risk Diff (95% CI) = 
1.4% (-9.8%, 12.6%), p = 0.812 N = 286  
Location (Non-Thalamic)  
Non-Thalamic - Alt: 60.6%, Sal: 54.7%. Risk Diff (95% 
CI) = 5.9% (-7.6%, 19.4%), p = 0.394 N = 205  
Severity Index 
Regression of Treatment by subject 
severity level 
Adj OR (95% CI) = 0.37 (0.31, 0.44), p < 0.001. Odds for 
mRS 0-3 decreases for each unit increase in severity score   
Severity score includes age, GCS, 
Thalamic location, Stab IVH, Stab 
ICH.  
Assignment to alteplase 
did not improve mRS but 
did improve mortality 
(See Suppl section 2d.) 
2.8. Functional Status     
NIHSS† Rank Sum Mean (SD) - Alt: 5.0 (7.0), Sal: 6.1 (7.9), p = 0.140 N (Alt) = 182, N (Sal) = 158  
Barthel‡ Rank Sum Mean (SD) - Alt: 65.2 (37.7), Sal: 69.5 (35.1), p = 0.312 N (Alt) = 197, N (Sal) = 170  
eGOS§ (>= Up SD v. <= Low SD) Chi-Square Test  
Alt: 39.4%, Sal: 32.0%. Risk Diff (95% CI) = 7.5% (-
1.1%, 16.0%), p = 0.087     
eGOS§ (>= Up SD v. <= Low SD) Multivariable Logit Model 
Adj OR (95% CI) = 1.53 (0.97, 2.41), p = 0.069. OR for 
>= Up SD; Alt v. Sal.  
Adj for Age, GCS, Thal, Stab ICH, 
Stab IVH (cat)   
eGOS§ ordinal  
Generalized Ordinal Model 
Test of Proportionality unadjusted eGOS  
(chi 2 p = 0.306 for Prop Odds) 
OR (95% CI) = 0.67 (0.48, 0.93), p = 0.016. OR for 
eGOS > K v. <= K; Alt v. Sal.  
Reverse coded: 5 - death, 4 - VS+low 
SD, 3 - up SD, 2 - MD, 1 – GR 
Proportional shift favors 
alteplase when all levels 
of eGOS considered. 
eGOS§ ordinal  
Adjust Gen Ordered Logit Model for 
Ordered Data 
Adj OR (95% CI) = 1.40 (0.67, 2.92), p = 0.370. Adj OR 
for eGOS MD or worse v.  GR; Alt v. Sal.  
Reverse coded: 5 - death, 4 - VS+low 
SD, 3 - up SD, 2 - MD, 1 – GR  
  
Adj OR (95% CI) = 0.93 (0.56, 1.54), p = 0.786. Adj OR 
for eGOS Up SD or worse v.  MD + GR.; Alt v. Sal.  
Partial Proportional Odds Model: GR 
(low + up) and MD (low + up) 
identical  
 
Test of proportionality, (VS+low SD), 
and MD, GR assumed identical (chi 2 
p=0.080). 
Adj OR (95% CI) = 0.61 (0.39, 0.94), p = 0.025. Adj OR 
for eGOS (VS+low SD) + Death v.  Up SD + MD+ GR; 
Alt v. Sal.   
eGOS identifies groups 
different for VS, low SD, 
and mortality 
  
Adj OR (95% CI) = 0.48 (0.30, 0.77), p = 0.002. Adj OR 
for eGOS Death v. (VS+ low SD) + Up SD + MD + GR.; 
Alt v. Sal.   
eGOS identifies groups 
different for mortality 
     
2.9. QoL T-test   QoL not different by Grp 
SIS‖ (Strength)  Mean - Alt: 55.0, Sal: 58.8, p = 0.312   
SIS‖ (Mobility)  Mean - Alt: 58.3, Sal: 60.1, p = 0.652   
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SIS‖ (Hand Function)  Mean - Alt: 53.4, Sal: 56.5, p = 0.478   
SIS‖ (ADL)  Mean - Alt: 59.3, Sal: 61.2, p = 0.634   
SIS‖ (Communication)  Mean - Alt: 76.0, Sal: 79.6, p = 0.255   
SIS‖ (Thinking)  Mean - Alt: 58.5, Sal: 62.7, p = 0.224   
SIS‖ (Emotion)  Mean - Alt: 73.1,  Sal: 73.5, p = 0.882   
SIS‖ (Participation)  Mean - Alt: 47.5, Sal: 49.6, p = 0.551   
EuroQol Vas¶  Mean (SD)  - Alt: 62.8 (26.0), Sal: 65.1 (23.3), p = 0.376    
     
  Accept Null    
  p<0.05 – Reject Null    
*Scores on the modified Rankin Scale (mRS) range from 0 (no disability) to 5 (severe disability) to 6 (death); for ordinal analysis, mRS 0 and 1 combined 
†Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 (no disability) to 42 (severe disability) 
‡Scores on the Barthel Index (BI) range from 0 (unable to perform any) to 100 (able to perform all) activities of daily living 
§Scores on the Extended Glasgow Outcome Scale (eGOS) range upper good recovery to death 
‖Scores on the Stroke Impact Scale (SIS) range from 1 (most impaired) to 5 (no impairment) on 16 activity domains 
¶Scores on the EuroQuol Visual Analog Scale (EQ-VAS) range from 0 (worst) to 100 (best) imaginable health state 
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4b. Table S2. eGOS score frequencies for the 30, 180, and 365 day time points. 
 
 Visit and Treatment 
 30 days 180 days 
eGOS Saline Alteplase Saline Alteplase 
Upper GR 4 1.62 3 1.23 17 7.05 15 6.22 
Lower GR 4 1.62 1 0.41 5 2.07 6 2.49 
Upper MD 2 0.81 10 4.12 12 4.98 13 5.39 
Lower MD 4 1.62 9 3.70 10 4.15 19 7.88 
Upper SD 19 7.69 19 7.82 33 13.69 42 17.43 
Lower SD 132 53.44 138 56.79 85 35.27 92 38.17 
VS 46 18.62 41 16.87 6 2.49 8 3.32 
Dead 36 14.57 22 9.05 73 30.29 46 19.09 
Totals 277 100.0 243 100.0 241 100.0 241 100.0 
 
 
4c. Table S3. Univariable and Multivariable Analyses of Dichotomized mRS Modified Rankin Scale (mRS) Score at Day 180 
(mRS 0-3 vs. 4-6);  Illustrating the Influences of Treatment (alteplase vs. saline), Several Disease Factors, and Effect of Clot 
Removal on mRS score at Day 180 Outcome. 
 
 Univariable (Unadjusted) Models 
Multivariable  
Model 1 
(All Patients) 
Multivariable  
Model 2 
(Treatment by IVH 
interaction at 20 mL)1 
Variables 
 OR
2 [95% CI] AOR3 [95% CI] AOR [95% CI] 
Age 
(per year increase) 
0.94* 
[0.93, 0.96] 
0.95* 
[0.93, 0.97] 
0.94* 
[0.92, 0.96] 
Randomization GCS† 
(per unit increase) 
1.27* 
[1.20, 1.36] 
1.21* 
[1.13, 1.30] 
1.21* 
[1.12, 1.30] 
ICH Location 
(Thalamic v. Other) 
0.45* 
[0.31, 0.65] 
0.46*** 
[0.26, 0.83] 
0.44** 
[0.24, 0.81] 
Stability ICH  
(per mL) 
0.90* 
[0.87, 0.92] 
0.90* 
[0.87, 0.94] 
0.89* 
[0.86, 0.93] 
AUC normalized 
(per mL of time-weighted clot 
volume remaining) 
0.96* 
[0.95, 0.98] 
0.96* 
[0.94, 0.97]  
Treatment – All Patients 
(rt-PA v. saline)  
1.11 
[0.78, 1.59] 
0.92 
[0.59, 1.44]  
    
Treatment – IVH > 20 mL 
(alteplase vs. saline) 
1.36 
[0.84, 2.23]  
1.87*** 
[1.02, 3.43] 
1 Model also adjusts for stability IVH; 2 OR: odds ratio; 3 AOR: adjusted odds ratio  
† Scores on the Glasgow Coma Scale (GCS) range from 15 (fully conscious) to 3 (deep coma) 
*p < 0.001; **p < 0.01; ***p < 0.05      
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4d. Table S4. Additional outcome variables by group.  
 
Outcome Variables Alteplase (N=249) 
Saline 
(N=251) p-value 
eGOS§ ≥ Upper SD at 180 days: no. (%) 95 (39) 77 (32) 0.087 
Time to Home‖: Median (25th percentile)  95 (42) 107 (50) 0.771 
Location at D180: no. (%) 249 (100) 251 (100)  
Home: no. (%) 
Rehab Unit: no. (%) 
Acute: no. (%) 
Long-Term Care Facility: no. (%) 
Dead: no. (%) 
Missing: no. (%) 
1378 (55) 
27 (11) 
4 (2) 
343 (143) 
46 (18) 
1 (<1) 
1243 (49) 
18 (7) 
5 (2) 
29 (12) 
73 (29) 
32 (1) 
0.062 
EuroQoL Visual Analog Scale (EQ-VAS) ¶: Median 
[IQR] 70 [50, 80] 70 [50, 80] 0.497 
Barthel Index (BI) [1]: Median [IQR] 85 [30, 100] 85 [45, 100] 0.312 
§Scores on the Extended Glasgow Outcome Scale (eGOS) range from upper good recovery to death 
‖25th percentile provided in place of IQR. Data censored at 180 days for analysis and 75% of subjects were not yet home. 
¶Scores on the EuroQuol Visual Analog Scale (EQ-VAS) range from 0 (worst) to 100 (best) imaginable health state 
[1]Scores on the Barthel Index (BI) range from 0 (unable to perform any) to 100 (able to perform all) activities of daily living 
 
4e. Table S5. Primary reason for exclusion by count and frequency. 
 
Primary Exclusion Criteria Subject Count 
(n=9,784) 
Frequency 
(%) 
Structural etiology (aneurysm, Moyamoya, etc.) 1,312 13.4 
Outside allowed age range 1,280 13.1 
Lack of 3rd/4th obstruction 1,266 12.9 
ICH volume greater than 30cc 1,250 12.8 
No EVD placed 1,239 12.7 
Infratentorial involvement 739 7.6 
DNR status 347 3.6 
Historic Rankin 158 1.6 
Uncontrolled PTT, PLT, INR 157 1.6 
Other Exclusion 2,036 20.7 
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4f. Table S6. Demographics for screen failures vs. enrolled subjects. 
 
Demographic Screen Failures (n=9,784) 
Enrolled 
(n=500) 
p-Value 
(Chi-Square w/Yates) 
Gender    
0.156 
   Female 4,604 (47.1%) 222 (44.4%) 
   Male 5,138 (52.5%) 278 (55.6%) 
   Unspecified 42 (0.4%) 0 (0.0%) 
Primary Diagnosis    
   ICH with IVH 7,604 (77.7%) 428 (85.6%) 
<0.00001    Primary IVH 1,286 (13.1%) 72 (14.4%) 
   Unspecified 894 (9.1%) 0 (0.0%) 
Race    
   White 6,624 (67.7%) 306 (61.2%) 
<0.00001 
   African-American 1,762 (18.0%) 170 (34.0%) 
   Asian 358 (3.7%) 14 (2.8%) 
   Other/Unspecified 1040 (10.6%) 10 (2.0%) 
       
4g. Table S7. Proximate causes of death.  
 
Proximate causes of death for subjects who died prior to 30 days and 30 or more days post symptom onset but prior to completing the 
day 180 visit.  
 
 < 30 Days 30-180 Days 0-180 Days Combined 
Proximate Cause of Death Alteplase Placebo Total Alteplase Placebo Total Total 
Neurologic no. (%) 17 (73.91) 26 (74.29) 43 (74.14) 7 (30.43) 13 (34.21) 20 (32.79) 63 (52.94) 
Cardiac no. (%) 3 (13.04) 3 (8.57) 6 (10.34) 3 (13.04) 6 (15.79) 9 (14.75) 15 (12.61) 
Respiratory no. (%) 2 (8.70) 2 (5.71) 4 (6.90) 3 (13.04) 8 (21.05) 11 (18.03) 15 (12.61) 
Renal no. (%) 0 (0.00) 0 (0.00) 0 (0.00) 1 (4.35) 1 (2.63) 2 (3.28) 2 (1.68) 
Gastrointestinal no. (%) 1 (4.35) 0 (0.00) 1 (1.72) 1 (4.35) 0 (0.00) 1 (1.64) 2 (1.68) 
Infection, non-neurologic no. (%) 0 (0.00) 3 (8.57) 3 (5.17) 4 (17.39) 2 (5.26) 6 (9.84) 9 (7.56) 
Unknown no. (%) 0 (0.00) 1 (2.86) 1 (21.52) 4 (17.39) 8 (21.05) 12 (19.67) 13 (10.92) 
Total no. 23 35 58 23 38 61 119 
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4h. Table S9. Premorbid, historical modified Rankin Scale scores by treatment group. 
 
 
Historical mRS* Alteplase Saline Total 
0 no. (%) 219 (50.1) 218 (49.9) 437 (100) 
1 no. (%) 30 (48.4) 32 (51.6) 62 (100) 
2 no. (%) 0 (0.0) 1 (100.0) 1 (100) 
Total no. (%) 249 (49.8) 251 (50.2) 500 (100) 
*Scores on the modified Rankin Scale (mRS) range from 0 (no disability) to 5 
(severe disability) to 6 (death) 
 
4i. Table S10. Effect of treatment on mortality by age (data from Figure S4 in tabular format) 
 
 5 Age Categories 
Treatment <50 50 - <60 60-<65 65-<70 70+ 
Saline (n) 49 81 35 35 51 
Mortality % 14.0% 25.0% 31.0% 34.0% 45.0% 
      
Alteplase(n) 58 75 45 29 42 
Mortality % 10.0% 16.0% 13.0% 28.0% 33.0% 
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4j. Table S11. Summary of Key Primary and Secondary Analyses and Results from Supplemental Table S1. 
 
PRIMARY 
   Saline – Alteplase 
Difference (95% CI) 
 
1.1 Functional Outcome 3% increase mRS 0-3 3 (-6, 12) p=0.587 
1.2 – 1.5 Alt. Analyses of mRS Levels mRS 6 half as likely with alteplase 0.5 (0.4, 0.8) p<0.001 
KEY SECONDARY  
2.1 180-day Mortality Outcome 11% decrease with alteplase 11 (3, 8) p=0.007 
2.2 Clot Removal Associated with greater % mRS 0-3 --- p<0.001 
2.3 ICU Care No difference  p=0.098 
2.4 30-day Mortality/Safety Trend favors alteplase  p=0.055 
2.5 Safety-AEs/SAEs 14% fewer SAEs with alteplase 
5% less ventriculitis @ 180 days with alteplase 
-14 (-23, -6) 
-5 (10.7, 0.4) 
 
p=0.001 
p= 0.047 
 
2.6 Predictors of Mortality Adjusted hazard of death 0.58 0.5 (0.4, 0.9) p=0.005 
2.7 Sub-group No differences  NS (all listed in 
Table S1) 
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